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Summary 
This study highlights the importance of rapid identification of drug-resistant tuberculosis 
and the complex network of mechanisms that regulates drug resistance in the bacteria. 
Tuberculosis control revolves around rapid detection and diagnosis of the disease to 
initiate effective treatment as soon as possible. The emergence and subsequent 
transmission of drug-resistant Mycobacterium tuberculosis strains has complicated 
controlling this disease. Various phenotypic and genotypic methods have been employed 
for the detection of resistance to anti-tuberculosis drugs. Phenotypic methods are 
technically demanding and time consuming due to the slow-growing bacterium. One 
example is to test for pyrazinamide resistance. Pyrazinamide is only active at low pH, 
thereby complicating susceptibility testing due to poor growth and subsequent death of 
mycobacteria in the test medium. For these technical reasons, pyrazinamide susceptibility 
testing is not done routinely in many countries. The extent of pyrazinamide resistance is 
therefore unknown in South Africa. Alarmingly, it was observed that more than 50% of 
patients infected with a drug-resistant tuberculosis strain are phenotypically and 
genotypically resistant to pyrazinamide. Genotypic resistance is mostly attributed to 
mutations scattered in the pncA gene. This makes it difficult to develop a molecular 
method to rapidly detect pyrazinamide resistance. Failure to detect resistance to this first-
line drug will result in inappropriate therapy which may lead to prolonged treatment. This 
has negative implications for the Tuberculosis Control Program. Therefore, pyrazinamide 
testing is essential to ensure effective treatment for tuberculosis patients.  
 
Another first-line drug, rifampicin, is promoted as a marker for the identification of 
multi-drug resistant tuberculosis. Various molecular methods have been employed to 
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identify mutations associated with rifampicin resistance in this pathogen. Recently, a 
newly identified nucleotide change (Rv2629 191A/C) was reported to confer rifampicin 
resistance. In contrast, we have shown that this nucleotide change was not associated 
with rifampicin resistance, but was significantly associated with the Beijing lineage of 
M. tuberculosis. This nucleotide change is a useful marker to identify the Beijing 
lineage that is widely distributed in various parts of the world. 
 
This study has provided the first evidence that variation in the level of rifampicin 
resistance in closely related clinical isolates of M. tuberculosis is more complex than the 
central dogma suggests. Hyper-resistance can not be explained solely on the basis of 
mutations in the rpoB gene that confer resistance to rifampicin. We have provided 
evidence that exposing rifampicin resistant M. tuberculosis strains to efflux pump 
inhibitors, reserpine and verapamil, together with rifampicin, significantly reversed the 
rifampicin resistance phenotype to become rifampicin susceptible. This has far-reaching 
therapeutic implications for the treatment of tuberculosis when used in combination 
with anti-tuberculosis drugs. With this knowledge, we proposed a model that predicts 
the evolution of the level of rifampicin resistance. Subsequent transcriptomic analysis of 
numerous transporter genes identified potential candidates for functional assays and 
future drug design.  
 
This innovative research enables scientists to re-investigate existing ideas, thereby 
shifting paradigms, challenging scientific dogmas and ultimately unraveling the 
mysteries regarding drug resistance in this pathogen.  
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Opsomming 
Hierdie studie beklemtoon die belangrikheid van vinnige identifikasie van 
middelweerstandige tuberkulose en die komplekse netwerk van meganismes wat 
weerstandigheid in die bakterium reguleer. Vinnige diagnose is noodsaaklik om 
spoedige behandeling te verskaf en tuberkulose te beheer. Die verskyning van 
middelweerstandige Mycobacterium tuberculosis stamme bemoeilik die verdere beheer 
van hierdie siekte. Verskeie fenotipies en genotipiese metodes word gebruik om 
weerstandigheid teen anti-tuberkulose middels te bepaal. Fenotipiese metodes is egter 
tydrowend en vereis ‘n hoë mate van tegniese vaardigheid. Een voorbeeld is die toetsing 
vir weerstandigheid teen Pirasinamied. Hierdie middel is slegs aktief by ‘n lae pH. Dit 
bemoeilik die toets as gevolg van die swak groeiende bakterie in die toetsmedium. 
Weerstandigheid van Pirasinamied word om hierdie rede  nie as roetiene gedoen nie. 
Die voorkoms van Pirasinamied weerstandigheid in Suid-Afrika is dus onbekend. Die 
studie maak die onstellende observasie dat meer as 50% van pasiente wat weerstandig is 
teen een of meer anti-tuberkulose middel ook fenotipies en genotipies weerstandig is 
teen Pirasinamied. Genotipiese weerstandigheid word toegeskryf aan mutasies wat 
verspreid in die pncA geen voorkom. Dit bemoeilik die ontwikkeling van molekulêre 
metodes vir vinnige diagnose. Die onvermoë om weerstandigheid teen hierdie eerste-
linie middel te bepaal lei tot onvoldoede behandeling. Dit hou negatiewe gevolge vir die 
Tuberkulose Beheer Program in. ‘n Toets vir Pirasinamied weerstandigheid is dus 
noodsaaklik om te verseker dat tuberkulose pasiënte op effektiewe behandeling is.  
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Nog ’n eerste-linie middel, Rifampisien, word beskou as ’n merker vir die identifikasie 
van multi-weerstandige tuberkulose. Verskeie molekulêre metodes word gebruik om 
mutasies wat met rifampisien weerstandidgheid geassosieer word, te identifiseer. 
Onlangs is ’n nuwe nukleotied verandering (Rv2629 191A/C) gerapporteer wat 
weerstandigheid teen Rifampisien veroorsaak. In teenstelling, het ons bewys dat hierdie 
nukleotied verandering nie geassosieer word met rifampisien weerstandigheid nie, maar 
dat dit wel beduidend geassosieer word met die Beijing stamboom van M. tuberculosis. 
Hierdie verandering is dus ’n bruikbare merker vir identifikasie van die Beijing 
stamboom wat in verskeie dele van die wêreld voorkom.  
 
Die studie het eerste bewyse gelewer dat variasie in die vlakke van rifampisien 
weerstandigheid in verwante kliniese isolate van M. tuberculosis meer kompleks is as 
wat sentrale dogma beweer. Hiper-weerstandigheid kan nie net verduidelik word op 
grond van mutasies in die rpoB geen wat rifampisien weerstandigheid veroorsaak nie. 
Blootstelling van rifampisien weerstandige M. tuberculosis stamme aan middels 
(reserpine en verapamil) wat sal verhoed dat rifampisien deur die bakterie uitgepomp 
word, het getoon dat hierdie middels die vlakke van rifampisien sensitiwiteit beduidend 
beïnvloed. Dit het verrykende terapeutiese implikasies vir die behandeling van 
tuberkulose as dit in kombinasie met anti-tuberkulose middels gebruik kan word. Op 
grond van hierdie kennis is ’n model voorgestel van die evolusie wat die variërende 
vlakke van rifampisien weerstandigheid in die bakterie verduidelik. Deur 
transkriptomiese analise is ‘n aantal transporter gene geïdentifiseer wat as potensiële 
kandidate vir funksionele toetse en toekomstige middel ontwikkeling kan dien.  
 
 vii 
Hierdie innoverende navorsing bemagtig wetenskaplikes om bestaande idees weer te 
ondersoek en daardeur paradigmas te verskuif, wetenskaplike dogmas uit te daag en 
uiteindelik die raaisel omtrent weerstandigheid in die patogeen te ontrafel. 
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CHAPTER 1 
 
General Introduction 
1.1 BACKGROUND 
Mycobacterium tuberculosis (M. tuberculosis), the causative bacteria of tuberculosis (TB) 
in humans, is the leading cause of death by an infectious pathogen globally (3,15). The 
resurgence of TB can in part be attributed to the ability of the tubercle bacillus to adapt, 
evolve and become resistant to various anti-TB drugs. Multi-drug resistant (MDR) TB is 
defined as M. tuberculosis strains that are resistant to the two most important first-line 
drugs, Isoniazid (INH) and Rifampicin (RIF). Recently, extreme drug resistant (XDR) TB, 
the more severe and often frequently fatal form of drug resistance, has been identified in 
various parts of the world, including in South Africa (5,6). XDR-TB is defined by the 
World Health Organization (WHO) as M. tuberculosis strains that are MDR and in 
addition, also resistant to a Fluoroquinolone and one of the injectable drugs i.e. Kanamycin, 
Amikacin and Capreomycin. The emergence of MDR and now XDR M. tuberculosis 
strains is alarming and represents a worldwide threat to TB control (16,17). 
 
Recent, surveillance data reported that the TB incidence rate in South Africa is 600/100 000 
per annum (18). The WHO has also declared South Africa as one of the hot spots for MDR-
TB (17). In 2001, the WHO reported that MDR-TB was identified amongst 1.75% and 
6.95% for new and previously treated TB cases in South Africa (17). Findings from our 
laboratory indicate that more than 60% of drug resistance is due to transmission of an 
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already resistant strain (10-12). This is alarming and indicates that current control measures 
are inadequate to control the transmission of drug resistant TB strains. Furthermore we, and 
others have shown that resistance is due to a number of chromosomal mutations in specific 
genes of M. tuberculosis (14). Evidence of drug resistant mechanisms have been found 
through cloning  and characterization of these specific genes in drug resistant isolates (7). 
Drug susceptible isolates lack these corresponding mutations. Thus the identification of 
these resistance conferring mutations has been proposed as means to genetically identify 
drug resistance, in particular MDR-TB, thereby improving the time to diagnosis and 
preventing the transmission of drug-resistance. 
 
By application of molecular epidemiological approaches, we have shown that groups of 
closely related strains, [Beijing/W-like (28%), the IS6110 Low-Copy-Clade (LCC) (26%), 
F11 (12%) and F28 (5%)], represent 71% of the drug resistant isolates in the local study 
communities (10). Although the Beijing/W-like and LCC strain families are dominant 
amongst drug resistant isolates, it is striking that these strain families are not the most 
dominant amongst drug susceptible isolates from local communities. Furthermore it is 
unclear why certain family specific drug resistant strains transmit better than other strains 
from within the same strain family, despite the fact that the control program has remained 
constant. In this regard it is possible that prolonged exposure to sub-lethal levels of anti-TB 
drugs, such as in many TB cases in South Africa that do not adhere to anti-TB treatment 
(13), may render the organism increasingly resistant (as defined by minimum inhibitory 
concentrations) to one or more drugs during treatment. This prolonged exposure might aid 
in the evolution and adaptation of survival mechanisms. Under such conditions clinical 
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strains may become more fit and transmissible. Long term drug exposure might result in the 
induction of additional mechanisms which may include efflux pumps (3). Before the 
introduction of anti-tuberculosis drugs, the physiological role of influx and active efflux 
systems was to protect the bacterial cell from toxic compounds or metabolites. However, 
the continuous exposure of M. tuberculosis to anti-TB drugs provides an evolutionary 
pressure for the selection of mutants in which alterations in drug efflux/influx mechanisms 
confer drug-resistance. The completion of the whole genome sequence of M. tuberculosis 
H37RV has fuelled attempts for other clinical strains to be sequenced. The Family 11 MDR 
strain is the first drug resistant clinical strain that has been sequenced, followed by other 
MDR and XDR TB strains from our drug resistant strain bank (http://www.broad.mit.edu). 
Analysis of these genome sequences has shown the presence of multiple putative efflux 
pumps (2). These influx/efflux pumps are grouped into different transporter types based on 
bio-energetics and direction of drug translocation. One such example is the class ATP-
binding cassette (ABC) transporters that hydrolyse ATP to extrude the drugs out of the cell. 
The exposure of mycobacteria to various efflux pump inhibitors (EPI’s) such as Reserpine, 
Verapamil and carbonyl cyanide m-chlorophenylhydrazone (CCCP) has been shown to 
reduce the resistance levels of anti-TB drugs (1,9). Recently, it was also shown that 
putative efflux pump genes were upregulated in clinical isolates when exposed to anti-TB 
drugs, such as INH, RIF and Ethambuthol (4,8). Therefore, it is evident that prolonged 
exposure of M. tuberculosis to drugs may enable the bacteria to evolve and adapt 
mechanisms, such as efflux pumps, that may modulate the level of drug resistance.  
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1.2 PROBLEM STATEMENT 
Our observations indicate that certain drug resistant genotypes transmit better than others. It 
is possible that these genotypes have become increasingly resistant to anti-TB drugs due to 
mechanisms that are still undetermined. The inability to detect resistance to certain drugs 
may lead to transmission. In addition, unidentified mechanisms that may possibly promote 
strain fitness, also enables these genotypes to be transmitted. This study was designed to 
enhance the ability to detect drug resistance and to optimize the identification of 
mechanisms, in addition to gene mutations that would render the bacilli hyper-resistant to 
anti-TB drugs.  
 
1.3 OVERALL HYPOTHESIS: 
In this study we hypothesize that transmission of drug resistant strains is due to a 
combination of shortcomings in the TB control program and adaptive mechanisms that 
cause M. tuberculosis strains to become hyper-resistant to anti-TB drugs.  
 
1.4 OVERALL AIM: 
To identify the mechanisms that enable drug-resistant strains of M. tuberculosis to be 
transmitted. 
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Structure of Thesis: 
Each chapter is structured for potential publication. If the results in a specific chapter have 
not been published yet, the references were formatted according to instructions of the 
Journal of Clinical Microbiology. 
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CHAPTER 2 
 
A Balancing Act: 
The role of efflux/influx in the evolution of mycobacterial drug-resistance 
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ABSTRACT 
Many aspects of mycobacterial drug-resistance mechanisms remain unknown despite the 
availability of a number of whole genome sequences of drug-resistant and drug-susceptible 
clinical and laboratory strains of Mycobacterium tuberculosis. Recent research has 
primarily focused on the identification of gene mutations conferring drug-resistance. Those 
research activities largely ignore cellular processes that are in homeostasis and that influx is 
in balance with efflux. Before the introduction of anti-tuberculosis drugs, the physiological 
role of the intrinsic hydrophobic cell membrane and active efflux systems was to protect the 
bacterial cell from toxic compounds or metabolites. These mechanisms conferred an 
intrinsic level of resistance to modern day anti-tuberculosis drugs. Continuous exposure of 
Mycobacterium tuberculosis to anti-tuberculosis drugs provides an evolutionary pressure 
for the selection of mutants in which alterations in drug efflux/influx mechanisms confer 
drug-resistance. Understanding these mechanisms will help in developing tools to identify 
and combat drug-resistance. This review focuses on the importance of understanding the 
evolution of efflux/influx mediated drug resistance in mycobacteria. 
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1. Introduction 
Since the discovery of the tubercle bacillus by Robert Koch in 1882 (93), understanding the 
dynamics and survival mechanisms of this pathogen has led to more questions than 
answers. Despite stringent control strategies and many advances in our knowledge of the 
epidemiology of tuberculosis (TB) and the biology of the causitive agent Mycobacterium 
tuberculosis (M. tuberculosis), TB still remains one of the most common and deadly 
infectious diseases worldwide. The emergence of multi-drug resistant (MDR) TB 
(resistance to the first-line drugs Isoniazid (INH) and Rifampicin (RIF)) (36) and 
extensively drug resistant (XDR) TB (additional resistance to a Fluoroquinolone (FQ) and 
any one of the injectable drugs, Kanamycin (KANA), Amikacin (AMI) or Capreomycin 
(CAP)) (1,40,57) are a major concern in the control of the global TB epidemic. 
 
Resistance to anti-tuberculosis drugs develops by spontaneous mutation and the resulting 
resistant mutants are selected by subsequent treatment with anti-tuberculosis drugs for 
which the mutants are resistant.  Resistance to various first-line anti-TB drugs such as INH, 
RIF, Pyrazinamide (PZA), Ethambutol (EMB), and classes of second-line drugs (FQs, 
aminoglycosides, thionamides, peptides and cycloserines) is attributed to specific mutations 
in target genes or regulatory domains (10,11,28,59,90-92) (Table1). It is thus believed that 
a specific gene alteration (mutations, insertions or deletions) will alter the structure of the 
target protein, thereby influencing the degree of susceptibility to the drug (99). For 
example, the katG gene encodes for both catalase and peroxidise enzyme activity which is 
essential for the conversion of INH to its active form. Mutations in the katG gene lead to a 
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decrease in catalase activity, thereby resulting in less INH being activated and M. 
tuberculosis being resistant to high levels of INH (37). This relationship was confirmed by 
Ramaswamy et al. who showed that INH resistant isolates with a minimum inhibitory 
concentration (MIC) of >256µg/ml INH all had low or no catalase activity levels (74). In 
contrast, mutations in the regulatory or structural regions of the inhA gene results in low 
level resistance to INH in M. tuberculosis (38,74). Interestingly, mutations within the 
promoter and the coding region of inhA were found to also confer ETH resistance (7,59). 
This demonstrates that mutations in the same genes or regulatory domain can result in 
different drug resistance phenotypes.  
 
However, resistance in a proportion of clinical M. tuberculosis isolates cannot be explained 
by classical gene mutations such as those described above. For example, approximately 20-
30% of clinical INH resistant M. tuberculosis isolates do not have mutations in any of the 
known genes (Table1) associated with INH resistance (73,74). Similarly, approximately 5% 
of clinical RIF resistant M. tuberculosis isolates do not harbour mutations in the Rifampicin 
Resistance Determining Region (RRDR) of the rpoB gene (95). Therefore, it is evident that 
other more esoteric mechanisms could play a role in drug resistance. 
 
Additional mechanisms of drug resistance in mycobacteria include the production of drug 
modifying and inactivating enzymes. These mechanisms include resistance associated with 
gene mutations, production of modifying enzymes that inactivate the active metabolites, 
low cell wall permeability and efflux related mechanisms (2,9,12,73,102,103). 
Mycobacteria produce enzymes that degrade or modify defined antibiotics leading to 
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inactivation (53,94). For example, Mycobacterium smegmatis (M. smegmatis) is naturally 
resistant to RIF, although no mutations have been identified in the rpoB gene (72). This 
suggests that an alternative mechanism plays a role in conferring resistance to RIF. In 1995, 
it was reported that M. smegmatis DSM43756 inactivates RIF by ribosylation, whereby a 
ribose ring is covalently linked to the RIF molecule (17,42). Gene disruption experiments 
provided evidence that RIF inactivation via ribosylation was the principal contributor of 
RIF resistance in M. smegmatis (72). However, only limited data exists for the production 
of degrading and drug modifying enzymes in M. tuberculosis. It has been reported 
previously that bacterial resistance to aminoglycosides can be attributed to enzymatic 
inactivation of aminoglycosides by phosphotransferases, nucleotidyltransferases and 
acetyltransferases (18). Acetyltransferase AAC (2’)-Ic and the phosphotransferase encoded 
by Rv3225c gene, has been shown to display aminoglycoside modifying activity (25) that 
resulted in resistance to aminoglycosides in mycobacteria. 
 
In order to design new anti-TB drugs and to develop novel diagnostics it is essential to gain 
an in depth insight into the mechanisms, other than the classical nsSNPs in known target 
genes, that confer resistance.  This is of particular importance since pathogenic 
mycobacteria, such as M. tuberculosis, are becoming increasingly resistant to many of the 
first and second line anti-TB drugs. This review gives a broad perspective on the regulation 
of intracellular anti-TB drug concentration by efflux related mechanisms in mycobacteria.  
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2. Mechanisms of the mycobacterial intrinsic resistome 
The intrinsic resistome is an evolutionary ancient phenotype, and can be defined as the 
intrinsic resistance of any bacterial species that has not been acquired as a result of recent 
use of antibiotics (27), and is therefore independent of previous antibiotic selective 
pressure. Intrinsic resistance is usually the result of reduced permeability of the bacterial 
envelope and the activity of multidrug efflux pumps (62). This suggests that the main 
physiological roles of the components of intrinsic resistance is the prevention of influx of 
toxic components by restricting permeability of the cell or the active transportation of the 
metabolites or toxic compounds out of the cell.  
 
In mycobacteria, the influx of toxic compounds is significantly restricted by the complex 
cell wall and lipid bilayer. This waxy lipid-rich cell wall comprising three covalently linked 
molecules i.e peptidoglycan, arabinogalactan and mycolic acid presents a significant barrier 
to the penetration of antibiotics (9). The reduction in membrane permeability leads to a 
decrease in the influx of the drug, thus leading to a decrease in the intracellular drug 
accumulation (61,66,99).  
 
DNA sequencing has predicted the genome of M. tuberculosis strain H37Rv encodes 
multiple putative efflux proteins, of which the majority have not yet been characterized 
(2,99). These efflux pump mechanisms probably have a pre-existing physiological role and 
protect the bacillus against low intracellular levels of toxic molecules and metabolites and 
maintain cellular homeostasis and physiological balance through transport of the toxins to 
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the extracellular environment. Recent evidence suggests that mycobacteria extrude multiple 
drugs (53,94,98) via active efflux systems (55,66,77). However, the efflux of a broad range 
of structurally unrelated toxic compounds can be considered to be an “accidental and 
opportunistic” side effect of the transport of unidentified physiological substrates 
(12,13,71,107). Some efflux pumps are specific for certain antibiotics whilst others extrude 
promiscuous structurally and functionally unrelated compounds as is the case for Multi 
Drug Resistance (MDR) efflux pumps (49,53,55). Experimental procedures for the 
identification of these pumps are limited to laboratory-induced mutants over-expressing 
efflux pumps. It was suggested by Gagneux et al. that clinical isolates have undergone 
more adaptation than laboratory-induced mutants (29). However, very few studies have 
been done on clinical isolates and the specific conditions required for the induction of these 
pumps are not known yet, although it is well recognised that expression of efflux pump 
genes is tightly  regulated (62,71,76). This ensures that efflux pump genes are available 
when required by the cell to perform their physiological function.  
 
2.1. Multi-Drug Resistance (MDR) efflux pumps 
MDR efflux pumps by definition reduce the intracellular concentration of more than one 
antibiotic to sub-inhibitory levels (53,55) and thereby are thought to promote the 
emergence of drug resistance. Genes encoding MDR efflux pumps are constitutively 
expressed in wild type cells (63) and thereby confer a low level of resistance. Current 
evidence suggests that M. tuberculosis contains more than one efflux pump capable of 
extruding more than one antibiotic, e.g. the Tap efflux pump that extrudes both 
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aminoglycosides and tetracyclines (TET) (2). MDR efflux pumps and transporters can be 
over-expressed due to mutations in regulatory regions (62). Alternatively, antibiotics can 
induce the expression of an MDR efflux pump by interacting with regulatory systems (76), 
e.g., TET-specific pumps possess regulatory controls that sense the presence of TET which 
acts as an inducer (33,34).  Both of the above mechanisms lead to an increase in the level of 
drug resistance. Thus, the inactivation or silencing of the efflux pumps (including MDR 
efflux pumps) could be a possible mechanism of controlling drug resistance. This would 
render the bacterium more susceptible, allowing lower doses of drugs to be used in the 
treatment of TB. 
MDR transporters are grouped into the following 2 major classes, based on their 
bioenergetic and structural profiles: 
 
2.1.1. Secondary multi- drug transporters (influx/efflux pumps) 
Secondary multi-drug transporters utilize the transmembrane electrochemical gradient of 
protons or sodium ions to extrude the drugs from the cell (19). They are divided into 4 
families; the major facilitator superfamily (MFS), the small multi-drug resistance family 
(SMR), the resistance nodulation cell division (RND) and multi-drug and toxic compound 
extrusion (MATE) family (2,49,55). Most RND proteins are either multi-drug or multi-
cation transporters (63) and are mostly found in gram negative bacteria. The SMR proteins 
bind cationic, lipophilic antibiotics and transport them across the membrane in exchange 
for protons. In M. tuberculosis, mmr is an example of an SMR protein that confers 
resistance to acriflavine, ethidiumbromide and erythromycin (6) (Table 2).  The expression 
of MFS and RND superfamily transporters is known to be subject to regulatory controls  
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(66,71,97). In some instances the transported substrates acts as the inducer, while in others 
the transported substrates acts as the repressor by binding to the specific regulatory 
domains thereby modulating gene expression. An example is the tap (tub) gene, encoding a 
homolog of tap(for) in M. tuberculosis called M.tb Tap/ Rv1258c. The expression of this 
transporter is dependent on the expression of multi-drug resistant effector gene, whiB7 (60).  
 
2.1.2. ATP-binding cassette (ABC) type multi-drug transporters 
ATP-binding cassette (ABC) type multi-drug transporters utilize the free energy of ATP 
hydrolysis to pump drugs out of the cell. The ABC transporters occupy about 2.5% of the  
total genome content of M. tuberculosis (12) and can be classified as importers or exporters 
based on the direction of translocation of their substrate as well as the orientation of  
receptors and channels (45,46). As their names suggest, importers are involved in the 
uptake of extracellular molecules while exporters export molecules from the cytoplasm to 
the external milieu. The ABC importers are composed of 4 domains: 2 membrane spanning 
domains (MSDs) associated with two cytoplasmic nucleotide domains (NBDs) (45). The 
NBDs show considerable sequence homology across the spectrum of ABC transporters. 
Sequence conservation is marked in 5 of the NBDs motifs. Two of the 5 motifs (namely 
WALKER A and WALKER B motifs) are present in a vast majority of ATP-binding 
proteins. The remaining 3 motifs characteristically consist of a signature, Histidine loop and 
Glutamine loop (39,100). Evidence suggest that phosphorylation of the NDB of the ABC 
transporter Rv1747, by serine/threonine kinase PknF is a possible mechanism of regulation 
of this transporter (58).  
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3. Evidence of efflux mechanisms leading to mycobacterial drug 
resistance. 
3.1. Isoniazid (INH) 
There is substantial evidence for efflux related mechanisms in M. smegmatis, which is 300 
fold more resistant to INH than M. tuberculosis. The overexpression of the M. tuberculosis 
mmpL7 gene in M. smegmatis confers high level INH resistance. With the addition of efflux 
pump inhibitors (EPI’s) Reserpine, CCCP, ortho-vanadate, Reserpine and Verapamil in M. 
smegmatis (13), the level of INH resistance decreased. These results suggest that mmpL7 is 
involved in the energy-dependent efflux of INH (66). More evidence for efflux related INH 
resistance comes from analysis of the iniA gene in M. tuberculosis. It was shown, by gene 
knock-out experiments, that the iniA gene is essential for the activity of an efflux pump that 
confers resistance to INH and EMB (14) and that M. tuberculosis strains lacking the iniA 
gene showed increased susceptibility to INH. The iniA deletion also results in an 
accumulation of intracellular ethidium bromide thereby suggesting that iniA plays a role in 
efflux.  This was supported by the observation that on the addition of Reserpine, resistance 
to both INH and ethidiumbromide were reversed (14). Recent investigation of gene 
expression differences by qRT-PCR in clinical isolates of M. tuberculosis, showed that 
various MFS efflux pump genes (efpA, PstB, Rv1258c, Rv1410c) and ABC transporters 
(Rv1819c and Rv2136c) were overexpressed in the presence of INH (35,43,101). 
Collectively, these results suggest that INH resistance in M. tuberculosis may be attributed 
to mutations in known genes and could also be influenced or modulated by efflux related 
mechanisms. 
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3.2. Rifampicin (RIF) 
Although mutations in the rpoβ gene have been described in RIF resistant Mycobacterium 
avium (M. avium), many isolates from the M. avium and Mycobacterium intracellulare (M. 
intracellulare) group demonstrate a significant level of natural resistance to RIF, possibly 
as a result of an efficient permeability and exclusion barrier. Low-level RIF resistance in 
wild-type M. smegmatis, Mycobacterium aurum (M. aurum) and M. tuberculosis has been 
shown to be due to an efflux mechanism that extrudes the drug (69). Despite 95% of RIF 
resistant clinical M. tuberculosis isolates being attributed to mutations in the RRDR, there 
is evidence to suggest that efflux related RIF resistance mechanisms may play a role in M. 
tuberculosis as RIF has been shown to upregulate the expression of the tap-like pump, 
Rv1258c and other putative efflux pumps Rv1410c, Rv1819c, Rv2136c in a clinical isolate 
of M. tuberculosis (35,43,83). In addition, the inorganic phosphate importer PstB has been 
overexpressed in the presence of RIF  (35,43,67,78).  
 
3.3. Pyrazinamide (PZA) 
PZA resistance in M. tuberculosis is primarily attributed to a wide spectrum of mutations in 
the pncA gene that encodes the enzyme pyrazinamidase (PZase) (44,54,73) PZase activates 
PZA by converting it into active pyrazinoic acid (POA) (104). About 70% of PZA resistant 
clinical isolates can be attributed to mutations in the pncA gene (79,80,86). The pncA gene 
can also be inactivated by the insertion of IS6110, thereby conferring the resistance 
phenotype (50). However, studies by Zhang et al confirmed that efflux pumps also play a 
role in mycobacterial resistance to PZA (87,107). Notably, in non-tuberculous M. avium 
and M. smegmatis, natural resistance to PZA is not due to a defective pncA gene but is due 
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to a highly active efflux mechanism that extrudes the active POA from the cell as soon as 
PZA is converted by PZase (87). The unique susceptibility of M. tuberculosis to PZA is due 
to efficient PZase activity at acidic pH as well as to a defective POA efflux mechanism 
(107). The definitive components of the POA efflux mechanism remain to be described, 
although accumulation of radioactive POA in M. tuberculosis and its extrusion by non-
tuberculous mycobacteria have been demonstrated (87).  The efflux pump inhibitor 
Reserpine has been shown to be an effective inhibitor of the POA efflux pump, increasing 
the susceptibility of M. tuberculosis to PZA by threefold (106).  
 
3.4. Fluoroquinolones (FQs) and Cationic dyes 
The FQs target and inactivate DNA gyrase and type II DNA topoisomerase (31,75), which 
are encoded by gyrA and gyrB respectively (75). Missense mutations within the Quinolone-
Resistance-Determining-Region (QRDR) have been identified and are associated with FQ 
resistance (31). However, not all FQ resistant clinical M. tuberculosis isolates can be 
explained by mutations in the gyrA and gyrB genes.  
 
An FQ efflux pump of the MFS superfamily, LfrA, was the first efflux pump to be 
described in M. smegmatis (52). LfrA exhibits broad substrate specificity to more 
hydrophilic FQs. When expressed on a plasmid, LfrA mediates low-level resistance to FQ’s 
and other toxic compounds such as ethidium bromide. The disruption of the lfrA gene in M. 
smegmatis causes increased sensitivity to ethidium bromide (52) and a minor decrease in 
the level of Ciprofloxacin (CIP) resistance (89).  
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Recently, it has been shown that fluoroquinolone resistant M. tuberculosis strains with 
mutations in the gyrA and gyrB genes were influenced by the efflux pump inhibitors 
MC207.110 and Reserpine. The levels of resistance for OFL and CIP were reduced 
between 2- and 6-fold (26). The disruption of the Pst phosphate-specific protein of M. 
smegmatis was also correlated with a decrease in CIP efflux. This resulted in an increased  
susceptibility to CIP, suggesting an involvement in the efflux of this antimicrobial agent 
(70). Pasca et al showed that the addition of the efflux pump inhibitor Reserpine to CIP 
resistant M. tuberculosis increased the intracellular accumulation of CIP. These results 
indicate that the Rv2686c-Rv2687c-Rv2688c proteins actively pump out CIP, probably by 
using ATP hydrolysis as an energy source (65) (Table 2). 
 
3.5 Aminoglycosides and Tetracyclines 
Streptomycin (STR), KANA and AMI are some of the known aminoglycosides used for the 
treatment of MDR-TB. The aminoglycosides target the 30S subunit of the ribosome by 
binding to the 16sRNA and S12 ribosomal proteins. Mutations in the rrs gene (encoding 
16sRNA) and the rpsL gene (encoding S12 protein) can confer resistance to the 
aminoglycosides (41,81,96). Recently, mutations in a highly conserved gene , gidB, was 
identified that functions as a rRNA methyltransferase. It was observed that mutations in 
gidB results in low level STR resistance (64). Approximately 65-67% of STR resistant 
clinical isolates harbour mutations in one of these two genes, however some resistant 
isolates lack identifiable gene mutations. It has been suggested that the blocking of STR 
uptake due to membrane impermeability (9) could explain resistance in these cases, 
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however, efflux related mechanisms leading to aminoglycoside resistance has been recently 
observed (12,85).  
 
A TAP multidrug efflux pump cloned from Mycobacterium fortuitum (M. fortuitum) and 
homologous to that of M. tuberculosis has been identified that confers low-level resistance 
to aminoglycosides and TET when expressed in M. smegmatis. Sequence analysis of the 
Tap gene predicts a protein exhibiting similarities to efflux pumps encoded by MFS (2). 
Another example of efflux related drug resistance to aminoglycosides and TET includes the 
characterization of the P55 protein isolated from M. bovis which was shown to be related to 
aminoglycoside and tetracycline efflux pumps in mycobacteria (84). Addition of CCCP, 
Verapamil and Reserpine to the strains expressing P55 decreased the MIC’s for both STR 
and TET. In contrast, the MIC level for both drugs in the control strain did not change. 
Results therefore indicate that resistance levels as a result of P55 were sensitive to the EPI’s 
and substances that eliminate proton gradient across membranes, suggesting that P55 uses 
energy from the proton gradient to drive transport of drugs (84). Other examples of 
aminoglycoside and TET related efflux include the expression of the ABC transporter 
genes drrAB in M. smegmatis, which confer resistance to a broad range of clinically 
relevant antibiotics, including TET, STR and EMB. The addition of Reserpine and 
Verapamil reversed the resistance phenotype (12). 
 
Recently it has been shown that the transcriptional regulator whiB7 of M. tuberculosis is 
upregulated in the presence of STR and KANA, although its target gene is yet to be 
determined (30). The phosphate-transport ATP-binding protein PstB was also shown to 
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extrude STR in M. smegmatis (35). For tetracycline specifically, an energy-dependent 
efflux pump Tet(V) was identified in M. smegmatis. The tet(V) gene encodes an efflux 
protein which uses proton motive force to extrude tetracycline from M. smegmatis. The 
Tet(V) protein is not homologous to any known specific TET efflux pump, and remains 
restricted to M. smegmatis and M. fortuitum species (22,51).  
 
4. Efflux pump genes not implicated in drug resistance 
Antibiotic resistance characteristics have facilitated the identification of many efflux 
proteins. However, efpA was discovered fortuitously during the screening of genes for 
novel M. tuberculosis membrane proteins (24). EfpA is predicted to be highly related to 
members of the QacA transporter family (Qac TF), which is also known as the drug 
resistance transporter family. Thus far, efpA has not been implicated in drug resistance, 
although all other members of the QacA TF mediate resistance to antibiotics. EfpA was 
detected in all drug-susceptible and drug-resistant M. tuberculosis isolates examined (24). 
 
5. Concluding remarks 
With the identification of chromosomal mutations in drug resistant pathogens, it was 
thought that the war against drug resistance in mycobacteria can potentially be won. 
However, the organisms have adapted their ancient mechanisms of toxin removal 
opportunistically to aid in fighting the battle against antibiotics. The opportunistic intrinsic 
resistance and the ability to evolve higher levels of resistance involve a complex network of 
non-classical antibiotic resistance genes and mechanisms. Therefore, the identification and 
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characterization of the genes and mechanisms forming these networks will contribute to the 
accurate prediction of the emergence of antibiotic resistance. In addition, it will help to 
define new potential drug targets against intrinsically resistant bacterial pathogens.  
 
Clinical use of compounds such as efflux pump inhibitors may serve to decrease intrinsic 
resistance in pathogens and lower the frequency of the emerging resistant mycobacterial 
strains. Therefore, it would be beneficial to inhibit efflux pump activity of a specific gene 
and thereby improve the clinical efficacy of various anti-TB drugs that are substrates of 
such efflux pumps.  
 
No new TB drugs have been developed and implemented into the TB treatment regime for 
40 years. Therefore, it is imperative to understand drug resistance mechanisms, specifically 
efflux related drug resistance, so as to aid in improving existing drug treatments, 
identifying new potential drug targets and to define new drug development strategies. A 
better understanding of these mechanisms will aid in the rapid detection and prevention of 
transmission of drug resistant M. tuberculosis strains (82) and can lead to more efficient 
anti-TB treatment.  
 
This review will be submitted to an international journal for potential publication. 
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Table 1: Genes associated with resistance to various anti-TB drugs  
Drugs 
Chemical 
properties 
of drug 
Discovery 
date 
Drug mode of 
action 
Gene Target enzyme References 
KatG catalase peroxidase 
InhA 
fatty acid enoyl acyl carrier 
protein reductase A 
ahpC 
alkyl hydroperoxidase 
reductase 
kasA B-ketoacyl-ACP synthase 
INH* Hydrophilic 1952 
Inhibits cell wall 
synthesis 
Ndh NADH dehydrogenase 
(47,73,75,105)  
RIF* Hydrophobic 1966 
Inhibits RNA 
synthesis 
rpoB 
B-subunit of RNA 
polymerase 
(73,75,91,105) 
rpsL 
Rrs STR*** Hydrophilic 1944 
Inhibits 
translation 
gidB 
16S rRNA ribosomal 
subunits 
(64,73,105) 
EMB* Hydrophilic 1961 
Inhibits cell wall 
synthesis 
embCAB arabinosyl transferase (73,105) 
pncA 
PZA* Hydrophilic 1952 
Disrupts 
plasmamembrane 
and energy 
metabolism 
IS6110 
insertion 
Pyrazinamidase, (79,105) 
gyrA 
FQ** Hydrophobic 1963 
Introduces 
negative 
supercoils in 
DNA molecules 
gyrB 
DNA gyrase (16,31,32,105) 
AMINO- 
GLYCOSIDES** 
Hydrophilic 1957 rrs, rpsL 
Rrs 
16S rRNA ribosomal 
subunits 
PEPTIDES** Hydrophilic 1957 
Inhibits 
translation 
tlyA  
(3,48,56,88,92,105)
InhA 
fatty acid enoyl acyl carrier 
protein reductase A 
ethA flavin monooxygenase 
ETH** Hydrophilic 1956 
Disrupts cell wall 
biosythesis 
ethR Transcriptional repressor 
(7,59,105) 
Legend to Table 1. INH-Isoniazid; RIF-Rifampicin; STR-Streptomycin; EMB-Ethambutol; PZA-Pyrazinamide; FQ-
Fluoroquinolones; VIO-Viomycin; CAP-Capreomycin; ETH-Ethionamide 
*First-line drug for the treatment of TB; **Second line drug for the treatment of MDR-TB; ***Alternative first-line drug 
for retreatment TB cases 
Note: The FQ for the treatment of MDR-TB consist of Moxifloxacin; Aminoglycosides consist of Kanamycin and 
Amikacin; Peptides consist of Capreomycin and Viomycin 
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Table 2: Reported putative efflux pump genes and transporters that may play a role in drug 
resistance in mycobacteria 
Gene 
Possible Drugs 
extruded 
Transporter  Function Protein Product Reference 
PstB INH, RIF, EMB, CIP ABC  
Active import of inorganic 
phosphate and export of drugs 
Phosphate-transport ATP-
binding protein 
(5,8,15,78) 
Rv2686c  CIP ABC Active transport of  drugs 
Integral membrane ABC 
transporter 
(8,15,65) 
Rv2687c CIP ABC 
Export of highly hydrophobic 
drugs 
Antibiotic transport integral 
protein 
(8,15,65) 
Rv2688c CIP ABC Export of toxic compounds 
Antibiotic-transport ATP-
binding protein 
(8,15,65) 
Rv1747 INH ABC  
Transport of drug across the 
membrane. 
conserved transmembrane 
ATP-binding protein 
(8,15) 
drrA TET, STREP, EMB ABC  
Export of antibiotic in the cell 
wall. 
ATP-binding protein drrA (8,12,15) 
drrB TET, STREP, EMB ABC  
Export of antibiotic in the cell 
wall. 
ATP-binding protein drrB (8,12,15) 
drrC TET, STREP, EMB ABC  
Export of antibiotic in the cell 
wall. 
ATP-binding protein drrC (8,12,15) 
Rv1348 Multiple Drugs ABC 
Active export/translocation of 
drugs across the membrane. 
Probable drugs-transport 
transmembrane ATP-binding 
protein 
(15) 
Rv1456c Undetermined ABC 
Active export of antibiotic 
across the membrane  
Integral membrane protein (15) 
Rv1463 Undetermined ABC 
Active transport and energy 
coupling across the membrane. 
Probable conserved ATP-
binding protein  
(15) 
Rv1258c 
INH, RIF, EMB, 
OFL 
MFS Export of drugs  Conserved membrane protein (15,20,43,83) 
Rv2994 Undetermined MFS Efflux of drugs Conserved membrane protein (15,20,51) 
Rv1877 
TET, KANA, 
Erythromycin 
MFS Efflux of drugs Conserved  membrane protein (15,20,51) 
Rv1634 Undetermined MFS Efflux of sugars and drugs 
Drug efflux membrane 
protein 
(15,19,20,51) 
efpA Possibly INH MFS Export of drugs 
Integral membrane efflux 
protein 
(15,24,51) 
Rv2333c Tetracycline MFS Efflux of drugs 
conserved integral membrane 
transport protein  
(15,20) 
Rv2459c Drugs MFS Transport of substrates 
conserved integral membrane 
transport protein 
(15,20) 
Rv3239c Sugar or drugs MFS could be involved in efflux  
conserved transmembrane 
transport protein  
(15,20) 
Rv3728 Sugar or drugs  MFS Involved in efflux  
conserved two-domain 
membrane protein  
(15,20) 
mmpL7 INH RND Export of antibiotic 
transmembrane transport 
protein 
(15,23,66,68) 
emrB Undetermined SMR  Export of multiple drugs 
Integral membrane efflux 
protein 
(15,21) 
whiB7 RIF regulatory protein Transcriptional regulation 
transcriptional regulatory 
protein  and effector gene 
(15,83) 
Rv2989 Undetermined 
transcriptional 
regulator 
transcriptional mechanism  
transcriptional regulatory 
protein 
(15) 
iniA INH, EMB Membrane protein Drug transport  INH inductible protein iniA (4,14,15)  
iniB INH Membrane protein Drug transport INH inductible protein iniB (4,14,15) 
iniC INH Membrane protein  Transcriptional mechanism INH inductible protein iniC (4,14,15) 
Rv1002c Undetermined Membrane protein Unknown function  Integral membrane protein (15) 
Rv3806c Undetermined Membrane protein Unknown Function Integral membrane protein (15) 
Rv3679 Undetermined ATPase Extrusion of  anions Probable anion transporter (15) 
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CHAPTER 3 
 
Frequency and implications of pyrazinamide resistance in managing 
previously treated tuberculosis patients. 
 
This chapter has been published in International Journal of Tuberculosis and Lung Disease [Int 
J Tuberc Lung Dis. 2006 Jul 10(7): 802-807]. The references were formatted according to the 
instructions of the journal.  
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SUMMARY 
 
Objective: To determine the extent of Pyrazinamide (PZA) resistance in isolates from 
previously treated patients from the Western Cape, South Africa.   
Design: Drug-resistant, resistant to one or more drugs other than PZA (PZA resistance is not 
routinely determined) (n=127), and drug-susceptible (n=47) clinical isolates of M. 
tuberculosis from previously treated patients from the Western Cape, South Africa, were 
phenotypically (BACTEC MGIT 960) and genotypically (pncA gene sequencing) analysed for 
PZA resistance.  
Results: MGIT analysis found that 68 of the 127 drug-resistant isolates were PZA resistant. 
Nearly all (63/68) PZA resistant isolates had diverse nucleotide changes scattered throughout 
the pncA gene and 5 PZA resistant isolates had no pncA mutations. Forty-six  of the forty-
seven phenotypically susceptible isolates were susceptible to PZA, while one isolate was PZA 
mono-resistant (OR = 53.0, 95% CI = 7.1-396.5). A pncA polymorphism (Thr114Met) not 
conferring PZA resistance was also identified. PZA resistance was strongly associated with 
multidrug-resistant TB (MDR-TB).  
Conclusion: An alarmingly high proportion of South African drug-resistant M. tuberculosis 
isolates are PZA resistant indicating that PZA should not be relied upon in managing patients 
with MDR-TB in the Western Cape, South Africa. A method for the rapid detection of PZA 
resistance would be beneficial in managing patients with suspected drug resistance.  
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INTRODUCTION 
Pyrazinamide (PZA) is an integral component of drug regimens for both drug sensitive and 
drug resistant TB. Because it is effective in the acidic microenvironment produced during 
acute inflammation, it is believed to play a unique role in killing a subpopulation of semi-
dormant TB bacilli that are not easily killed by other antibiotics.
1;2
 The addition of PZA to 
standard chemotherapeutic regimes for TB allowed the duration of therapy to be shortened to 
6 months and has been credited with the success of current DOTS strategy.
3
 Since PZA 
resistance is believed to be rare, the drug is also an important element in second line regimens 
used to treat MDR-TB for which rifampicin (RMP, R) and isoniazid (INH, H) are ineffective. 
 
PZA is a prodrug that is converted intracellularly to the active moiety, pyrazinoic acid (POA), 
by the mycobacterial enzyme pyrazinamidase (PZase).
1;2
 POA accumulates within 
M.tuberculosis bacilli when the extracellular pH is acidic.
4-6
 This accumulation of POA 
lowers the intracellular pH which is thought to lead to the inactivation of a vital target enzyme 
such as fatty acid synthase I (fasI).
3
  
 
Multiple studies have demonstrated that mutations in pncA, the gene that encodes for PZase, 
are a major mechanism of resistance to PZA.
7
 Previously identified mutations include 
missense mutations that cause amino acid substitutions, nucleotide insertions or deletions, and 
mutations in the putative promoter region of the pncA gene that alter gene expression. 
Although some researchers have found that most PZA resistant TB isolates have pncA 
mutations, others have reported that a substantial proportion of resistant strains lack these 
mutations and have proposed additional mechanisms of resistance including the non-uptake of 
the pro-drug.
7
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As PZA is only active at low pH (pH 5.5), susceptibility testing for PZA is complicated by the 
poor growth and subsequent death of mycobacteria at low pH in the test medium.
7;8
 For these 
technical reasons, PZA susceptibility testing is not done routinely in many countries and the 
extent of PZA resistance globally is largely unknown.  
 
Over the past decade, the prevalence of MDR-TB has increased in parts of South Africa. 
While a study conducted in the early 1990s in the Western Cape identified MDR-TB amongst 
1% of previously untreated cases,
9
 MDR-TB cases increased to 2% during 2001 to 2002.
10
 
 
In this study, we describe the phenotypic and genotypic identification of PZA resistance in 
clinical isolates of M. tuberculosis from the Boland/Overberg and South Cape/Karoo (BOKS) 
regions of South Africa. 
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STUDY POPULATION AND METHODS 
Study setting 
The study was conducted between September 2000 and December 2002 in 72 primary health 
care clinics in the BOKS region of the Western Cape Province, South Africa. The incidence 
of new smear positive TB cases in this province in 2002 was 571/100 000 population.
11
 TB 
cases were diagnosed by passive case finding and treated according to National TB Control 
Programme guidelines. Following DOTS recommendations, smear positive cases were treated 
for 2 months on a 4-drug Fixed Combination preparation (INH, RMP, PZA, ethambutol 
[EMB, E]). If patients remained smear positive after 2 months, sputum culture and drug 
susceptibility testing (DST) were performed and the patient was clinically reassessed. Routine 
DST was performed by the National Health Laboratory Services in Green Point by the 
indirect proportion method on Middlebrook 7H11 medium, and was therefore only available 
for previously treated patients. All drug-resistant patients were treated with individualized 
chemotherapy based on DST results and as specified by the patient’s physician. This study 
was approved by the ethics committee of Stellenbosch University, Tygerberg, South Africa. 
 
Isolates and DNA 
A total of 127 drug-resistant (resistant to one or more drugs other than PZA) M. tuberculosis 
isolates were analysed in this study. These isolates were randomly selected from previously treated 
patients attending clinics in the BOKS regions during the period from 22 February 2001 to 1 
December 2002. Genotyping showed that these drug-resistant isolates represent various highly 
prevalent M. tuberculosis drug-resistant genotypes from this region which include Beijing/W, 
F11, F28, LCC and unique genotypes which have been previously described in this region.
12
 
Strain families were defined according to IS6110 restriction fragment length polymorphism
 
analysis, with the dice coefficient and a similarity index of ≥65%. Spoligotyping confirmed 
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the presence of M. tuberculosis in all of the isolates analysed.
12;13
 Fourty-seven randomly 
selected drug-susceptible isolates, representing the same strain families as the drug-resistant 
isolates, collected from previously treated patients during the period from 17 January 2002 to 
1 December 2002 from the BOKS region were also available for this study. 
 
PZA susceptibility testing 
Susceptibility to PZA was tested by using the non-radiometric BACTEC Mycobacteria 
Growth Indicator Tube (MGIT) 960 method according to the BACTEC manual. The test 
medium is a modified Middlebrook 7H9 broth which supports the growth and detection of 
mycobacteria at a reduced pH of 5.9. The recommended critical concentration of 100µg/ml 
PZA was used in the BACTEC MGIT 960 test to discriminate between PZA susceptible and 
PZA resistant isolates. Four PZA resistant isolates from a supranational reference laboratory 
in South Africa were included as additional controls.  
 
PCR amplification of the pncA gene 
Using the genome sequence of the M. tuberculosis H37Rv reference strain 
(http://genolist.pasteur.fr/TubercuList) and DNAMAN version 4.1 software (Lynnon Biosoft, 
Vaudreuil-Dorion, Quebec, Canada), primers were designed to amplify a 615bp product 
which included the pncA coding region as well as flanking regions. The pncA F primer 5` 
AGTCGCCCGAACGTATGGTG 3` was designed to anneal –25bp upstream of the start 
codon (ATG) and the pncA R primer 5` CAACAGTTCATCCCGGTTCG 3`annealed 29 bp 
downstream of the stop codon. Purified mycobacterial DNA (2 µl) was added to PCR 
reagents which include 2x Q solution, 1x PCR buffer, 2mM MgCl2, 0.4mM dNTPs, 50 µM of 
each primer and 1.25U Hot Star Taq polymerase (Qiagen, San Diego, CA, USA). The PCR 
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reactions were performed under the following thermocycling conditions: 15 minutes (min) 
denaturation at 95 
o
C followed by 35 amplification cycles (each cycle: 94 
o
C for 1 min, 62 
o
C 
for 1 min, 1 min extension at 72 
o
C ) and the final elongation step of 10 min at 72 
o
C in a 
thermal cycler (Perkin Elmer Gene Amp PCR system 2400, Perkin Elmer, Cape Town, South 
Africa). Successful PCR amplification was confirmed by gel electrophoresis (100 Volts, 1 
hour) on a 2% agarose gel after staining with ethidium bromide. 
 
Sequencing of the pncA gene 
PCR products were cleaned with exonuclease I / shrimp alkaline phosphatase (Exo I and SAP-
IT) according to the instructions of the manufacturer (Amersham, Vienna, Austria). Typically, 
2µl of ExoSAP-IT (containing Exonuclease I and Shrimp alkaline phosphatase) was added to 
5µl PCR product. The reaction was mixed and incubated at 37
o
C for 15 min in a thermal 
cycler (PTC-100 Programmable Thermal Controller, MJ Research Inc, Ramsey, MN, USA). 
The enzymes were inactivated by heating to 80
o
C for 15 min and thereafter 7µl distilled water 
was added before DNA sequencing. The diluted products were sequenced (ABI PRISM DNA 
Sequencer model 377, Perkin Elmer) in both directions with the pncA F and pncA R primers, 
respectively. 
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism, Version 4.03. Differences between 
variables were expressed as odds ratio (OR) with 95% confidence intervals (95% CI).   
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RESULTS 
PZA resistance among drug-resistant clinical M. tuberculosis isolates from South Africa 
BACTEC/MGIT analyses showed that a total of 68 of the 127 (53.5%) drug-resistant isolates 
from previously treated patients were phenotypically resistant to PZA at a critical 
concentration of 100µg/ml PZA. Forty-six of the forty-seven (98%) isolates that were 
phenotypically susceptible to other drugs were found to be susceptible to PZA. However, one 
isolate (isolate S19) which was phenotypically susceptible to other drugs, was PZA resistant, 
suggesting PZA mono-resistance (OR = 53.0, 95% CI = 7.1-396.5) (Table).  
 
Correlation of mutations in the pncA gene with phenotypic resistance to PZA 
Of the 68 (93%) PZA-resistant isolates, 63 had nucleotide changes that include non-
synonymous mutations, insertions and deletions in the pncA gene that resulted in a change of 
the amino acid sequence of the PZase protein (Table). These mutations were diverse and 
scattered along the gene. The Figure shows the positions of the 28 different mutations found 
in the pncA gene, and illustrates the high diversity of mutations in the gene and the absence of 
a common hotspot for mutation. Five of the 68 (7%) PZA-resistant isolates did not have any 
pncA gene mutations. Re-testing these 5 isolates confirmed the PZA resistant phenotype. This 
suggests that another mechanism might be involved in conferring PZA resistance in these 
isolates. From these results it is evident that mutations in the pncA gene are common in the 
drug-resistant isolates from previously treated patients and that the pncA gene mutations 
correlate well with PZA resistance. 
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Some pncA mutations are not associated with resistance to PZA 
A non-synonymous nucleotide change (C→T at nt341, Thr114Met) in the pncA gene was 
identified in 10 of the 47 phenotypically susceptible isolates and was not found in any of the 
drug-resistant isolates. This nucleotide change did not confer the PZA resistance phenotype 
and can therefore be regarded as a polymorphism.  
 
PZA resistance is associated with MDR-TB.  
A total 62/68 (91%) drug resistant isolates that were phenotypically resistant to PZA were 
also resistant to INH and RMP (p<0.001). Therefore, it can be concluded that PZA resistance 
was strongly associated with MDR-TB. 
 
 
 
 
 
 
 
 
 
 
 
 
  
46
Table: Genotypic analysis of the pncA gene in the PZA-resistant isolates 
Family/ 
R numbers 
Resistance pattern 
Nucleotide 
substitution 
(position) 
Amino acid 
substitution 
Family/ 
R numbers 
Resistance pattern 
Nucleotide 
substitution 
(position) 
Amino acid 
substitution 
LCC    Beijing    
24 INH, RMP, SM 374 INH, RMP G→T (25) Val9Leu 
40 INH, RMP, SM, ETH 391 INH, RMP, SM, TH 
56 INH, RMP, SM 394 
INH, RMP, SM, 
ETH, KM 
T→C (40) Cys14His 
58 INH, RMP, SM 283 INH, RMP T→G (269) Ile90Ser 
63 INH, RMP, SM 405 INH, RMP, SM 
221 INH, RMP, SM 431 INH, RMP, SM 
C→G (309) Tyr103STOP 
432 INH, RMP, SM 462 INH, RMP, SM G→A (319) Glu107Lys 
543 INH, RMP, SM 328 INH, RMP 
619 INH, RMP, SM, KM 
Insertion of 
GG (389) 
Frameshift 
431 INH, RMP, SM 
G→C (554) Ser185Thr 
67 INH, RMP, SM 134* INH, RMP 
166 INH, SM 214* INH, RMP 
No mutation 
181 INH, SM F11    
212 
INH, RMP, EMB, SM, 
ETH, TH 
18 INH, RMP, OFX G→C (136) Ala46Pro 
223 INH, RMP, SM 269 INH, RMP 
309 INH, RMP, SM 398 INH, RMP 
T→C (202) Trp68Arg 
439 INH, RMP, SM 224 INH, RMP G→A (215) Cys72Tyr 
451 INH, RMP, SM 269 INH, RMP 
495 INH, RMP, SM 103 INH, RMP 
G→C (554) Ser185Thr 
498 INH, SM Unique    
577 INH, RMP, SM 82 INH, RMP, SM C→T (161) Pro54Leu 
599 INH, RMP, SM 
Deletion of T 
(172) 
Frameshift 
228 INH, RMP 
615 INH, SM A→C (535) Ser179Arg 351 INH, SM 
357 INH, RMP, SM G→C (554) Ser185Thr 371 INH, RMP, SM 
G→T (109) Glu37STOP 
364 INH, RMP, SM 371 INH, RMP, SM G→C (554) Ser185Thr 
478 INH, RMP, SM 
T→C (476) Leu159Pro 
202 
INH, RMP, ETH, 
TH, KM, OFX 
365 INH, RMP G→C (145) Asp49His 455 
INH, RMP 
C→T (169) His57Tyr 
118 INH, RMP, SM, ETH 455 INH, RMP G→C (554) Ser185Thr 
607 INH, RMP, SM 
G→A (415) Val139Met 
50 INH, RMP C→T (211) His71Tyr 
32 INH, RMP, SM 75 INH, RMP A→C (340) Thr114Pro 
597 INH, RMP, SM 
T→C (476) Leu159Pro 
75 INH, RMP A→C (535) Ser179Arg 
32 INH, RMP, SM G→C (554) Ser185Thr 270 
INH, RMP, SM T→G (94) Leu35Arg 
41 INH, RMP, SM, TH 124 INH, RMP, SM C→G (346) Leu116Val 
44 INH, RMP, SM 230 INH, RMP, SM A→G (407) Asp136Gly 
47 INH, RMP, SM 120 
INH, RMP, SM, 
EMB 
T→C (202) Trp68Arg 
323 INH, RMP, SM 108* INH, RMP 
381 INH, RMP, SM 219* INH, RMP 
479 INH, SM 463* INH, RMP, SM 
565 INH, RMP, SM 
T→G (202) Trp68Gly 
41 INH, RMP, SM, TH G→T (543) Glu181Asp 
S19 PZA† 
No mutation 
* PZA-resistant isolates with no pncA mutations 
† PZA-monoresistant isolate 
PZA= pyrazinamide; INH= isoniazid; RMP= rifampicin; SM= streptomycin; ETH= ethionamide; KM= kanamycin; TH= thioacetone; 
OFX= ofloxacin; EMB= ethambutol 
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GTG→TTG 
Val
9
Leu (*n=1) 
TCG→CGC 
Cys
14
His (n=2) 
CTG→CGG 
Leu
35
Arg (n=1) 
† 
GAA→TAA 
Glu
37
STOP (n=3) 
GCA→CCA 
Ala
46
Pro (n=1) 
GAC→CAC 
Asp
49
His (n=1) 
† 
CCG→CTG 
Pro
54
Leu (n=1) 
CAC→TAC 
His
57
Tyr (n=2) 
†
Deletion of T 
58 (n=12) 
TGG→CGG 
Trp
68
Arg (n=3) 
TGG→GGG 
Trp
68
Gly (n=7) 
‡
CAT→CGT 
His
71
Arg (n=3) 
‡
CAT→GAT 
His
71
Asp (n=1) 
CAT→TAT 
His
71
Tyr (n=1) 
† 
TGC→TAC 
Cys
72
Tyr (n=1)  
ATC→AGC 
Ile
90
Ser ((n=1) 
TAC→TAG 
Tyr
103
STOP (n=2) 
GAA→AAA Glu
107
Lys (n=1) 
§
ACG→ATG 
Thr
114
Met (n=10) 
ACG→CCG 
Thr
114
Pro (n=1) 
CTG→GTG 
Leu
116
Val (n=1) 
†
Insertion of GG 
130 (n=9) 
GAT→GGT 
Asp
136
Gly (n=1) 
GTG→ATG 
Val
139
Met (n=2) 
GTC→CCG 
Leu
159
Pro (n=4) 
AGC→CGC 
Ser
179
Arg (n=2) 
GAG→GAT 
Glu
181
Asp (n=1) 
† 
AGC→ACC 
Ser
185
Thr (n=8)  
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DISCUSSION  
Here we show that PZA resistance is common in drug-resistant clinical M .tuberculosis 
isolates from previously treated patients from the defined region and that there is a strong 
association (p<0.001) between mutations in the pncA gene and resistance to PZA. The 
mutations were highly diverse and scattered along the pncA gene. This diversity will make it 
difficult to develop a molecular based method, for rapid identification of PZA resistance other 
than sequencing the entire gene. Of the 28 (79%) previously described pncA gene mutations, 
22 were found to confer PZA resistance, as in other studies.
7;8
 In addition to previously 
described mutations in the pncA gene, we describe a further 6 mutations which confer PZA 
resistance. These mutations include a deletion of T at nt172, an insertion of GG at nt389, 
C→T at nt161 (Pro54Leu), G→A at nt215 (Cys72Tyr), G→T at nt109 (Gly37STOP), G→C at 
nt554 (Ser185Thr). We also describe a polymorphism, C→T at nt341 (Thr114Met) that is not 
associated with PZA resistance. Although pncA gene mutations are a major mechanism of 
PZA resistance, isolates without pncA mutations were also found to be PZA-resistant. This 
suggests the existence of a second mechanism involved in conferring PZA resistance. Zhang 
et al. provided direct evidence that efflux pumps play a role in mycobacterial resistance to 
PZA.
6;14
 
 
In this study, PZA resistance was strongly associated with MDR-TB. Patients can be infected 
by a PZA resistant M. tuberculosis strain due to 2 mechanisms. One of these may involve 
antibiotic selection and thus may reflect the manner in which these patients were treated prior 
to drug susceptibility testing. Currently, patients presenting for the first time are treated for 2 
months with a standardized intensive phase regimen (HRZE), followed by 4 month 
continuation phase (HR). Failure to respond will usually lead to DST. Therefore, if the strain 
is already resistant to INH and RMP, PZA drug-resistance could develop as result of the 
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failure of EMB to protect PZA or in the presence of INH, RMP and EMB resistance as the 
result of monotherapy. Patients presenting for retreatment will usually receive the World 
Health Organixation (WHO) recommended retreatment regimen of 2 months intensive phase 
treatment of HRZE + streptomycin (SM), 1 month of HRZE and 5 months of HRE, and DST 
will be requested at diagnosis. Again, resistance to INH and RMP, while awaiting the DST 
results, is dependent upon SM and EMB. Both SM and EMB are only moderately effective 
agents in this respect
15
. Should EMB resistance already exist, only SM will stand between 
PZA and the development of resistance. The other mechanism is via transmission of a PZA 
resistant M. tuberculosis strain, where a previous study has shown that transmission is a 
significant force driving drug resistant TB in this region
12
. The rapid detection of these 
resistant isolates would, of course, greatly assist the more effective management of these drug 
resistant patients and contribute to the prevention of further spread of these life-threatening 
bacilli. Scorpio et al. attempted to rapidly identify PZA resistant M. tuberculosis strains by 
direct sequencing of PCR products and PCR single-stranded conformational polymorphism 
(PCR-SSCP)
16
. However, the observation that PZA resistance is caused by multiple mutations 
in the pncA gene 
16
 makes the development of a molecular test for their rapid identification 
difficult. 
 
WHO guidelines for the management of a patient with apparent MDR-TB suggest two 
approaches depending upon whether the DST results are available
17
.  Should they not be 
available following the failure of the recommended retreatment regimen, a “third line” 
regimen is recommended. This should include at least 3 drugs never used: kanamycin, 
ethionamide and ofloxacin and pyrazinamide. If the DST results are available, an 
individualized regimen can be constructed, but, again the use of PZA is recommended. PZA 
has a limited role in preventing the emergence of drug resistance.
18
 However, it has been 
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proven in clinical trials that regimens containing PZA have a lower bacteriological relapse 
rate than regimens without PZA.
19
  
 
An interesting finding in Quebec, Canada is that many clinical isolates are PZA mono-
resistant and they all share the same pncA mutation profile.
20
 In a study from Peru 47 of 80 
(59%) MDR patients also had M. tuberculosis resistant to PZA.
21
 Our results indicate a 
similar level of PZA resistance amongst patients with MDR isolates. PZA resistance may thus 
be much more common than previously suspected and this confirms the dictum that it is 
unwise to place any reliance upon a drug to which the patient has previously been exposed 
when managing treatment failures. Further surveillance studies are needed to estimate the 
prevalence of PZA resistance in M. tuberculosis strains in South Africa. 
 
 
 
 
 
 
 
 
 
 
 
  
51
CONCLUSION 
This study highlights the presence of additional PZA resistance amongst patients with MDR-
TB in the Western Cape Province of South Africa. PZA susceptibility testing of M. 
tuberculosis isolates is not routinely done in this region and our findings indicate that PZA 
should not be relied upon in the management of patients with MDR-TB in the Western Cape. 
A methodology for the rapid detection of PZA resistance would be of considerable clinical 
benefit in managing patients with suspected drug resistance.  
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CHAPTER 4 
 
Rv2629 191A/C nucleotide change is not associated with  
Rifampicin  resistance 
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ABSTRACT  
A non-synonymous single nucleotide polymorphism (nsSNP) at position 191A/C in the 
Mycobacterium tuberculosis gene Rv2629 was recently identified by proteomics and 
sequencing and was reported to be significantly associated with Rifampicin (RIF) 
resistance. It was further claimed that this nsSNP could serve as a potential marker for the 
rapid diagnostics of multi-drug resistant tuberculosis. To test this hypothesis we quantified 
the frequency of this nsSNP in drug susceptible and drug resistant clinical isolates from 
different evolutionary lineages of M. tuberculosis. In contrast to the results reported 
elsewhere, our results showed that 191A/C Rv2629 was significantly associated with M. 
tuberculosis isolates from the Beijing evolutionary lineage (p<0.0001), irrespective of their 
RIF phenotype. Accordingly, we conclude that 191A/C Rv2629 is a polymorphism 
associated with the M. tuberculosis Beijing evolutionary lineage and does not confer RIF 
resistance. Thus, the 191A/C Rv2629 nsSNP cannot be used as a genetic marker of multi-
drug resistance.  
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TEXT  
In 1972 Rifampicin (RIF) was included in the treatment regimen as a first-line anti-
tuberculosis (anti-TB) drug due to it’s exceptional sterilizing activity. Together with 
Isoniazid (INH), Ethambutol (EMB) and Pyrazinamide (PZA), this drug forms an integral 
part of the current intensive and continuation phases of short-course treatment (1). 
Resistance to RIF is considered to be a reliable surrogate marker for multi-drug resistant 
TB (MDR-TB) (2). Therefore, identifying and understanding RIF resistance is of great 
importance and has led to the development of methods for the rapid identification of RIF 
resistance (2-4). These methods are based on the observation that ninety-five percent of RIF 
resistance can be attributed to mutations in the Rifampicin Resistance Determining Region 
(RRDR) of the Mycobacterium tuberculosis rpoβ gene (5). This suggests that other 
mechanisms or genes may be responsible for conferring RIF resistance in the remaining 5% 
of cases. In an attempt to discover such mechanisms, Wang et al used a proteomic approach 
to identify over-expressed proteins specifically associated with RIF-resistance (6). 
Sequencing of the gene Rv2629, encoding one of these over-expressed proteins, identified a 
non-synonymous nucleotide polymorphism (nsSNP) at codon 191A/C. The authors 
demonstrated that this nsSNP was significantly associated with RIF resistance in M. 
tuberculosis (6) and thereby concluded that this nsSNP was a potential biomarker for the 
rapid detection of RIF resistance in M. tuberculosis.  
 
To test this hypothesis, 90 RIF-resistant and 67 RIF-susceptible M. tuberculosis clinical 
isolates were randomly selected for analysis from a longitudinal collection of well 
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characterized clinical isolates. Each isolate was genotyped by spoligotyping (7) and 
grouped into major evolutionary lineages according to the presence of specific spoligotype 
signatures (8). The selected isolates were representative of prevalent M. tuberculosis 
evolutionary lineages, including the Beijing (28%), F11 (12%), F28 (5%), and  LCC (26%) 
lineages which together constitute 71% of drug resistant isolates cultured from cases in the 
Western Cape, South Africa (9). A 695bp fragment of the Rv2629 gene was amplified with 
primers that were previously described  (6). PCR reactions were performed under the 
following thermocycling conditions: 15 minutes (min) denaturation at 95
o
C followed by 40 
amplification cycles (each cycle: 94
o
C for 1 min, 62
o
C for 1 min, 1 min extension at 72
o
C ) 
and an elongation step of 10 min at 72
o
C. PCR products were cleaned with Exonuclease I / 
Shrimp Alkaline Phosphatase (Exo I and SAP-IT) according to the manufacturer’s 
instructions (Amersham, Vienna, Austria). The products were sequenced using an ABI 
PRISM DNA Sequencer model 377, Perkin Elmer. Statistical analysis was done using 
GraphPad Prism, Version 5.00.  
 
Sequencing analysis of the Rv2629 gene showed that the 191A/C nsSNP was present in 
48% (n = 43/90) of RIF-resistant isolates. This nsSNP was also present in 64% (n = 43/67) 
of RIF-susceptible isolates, thereby suggesting that the Rv2629 nsSNP was a polymorphism 
and was not associated with RIF-resistance. 
 
Grouping of isolates according to their spoligotype signatures showed that the Rv2629 
nsSNP was significantly associated with M. tuberculosis isolates of the Beijing 
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evolutionary lineage (p<0.0001). This association occurred irrespective of RIF-resistance 
phenotype (Table1). Accordingly, our results do not support the hypothesis put forward by 
Wang et al that the 191A/C nsSNP was a marker for RIF resistance in M. tuberculosis.  Our 
results confirm a recent report which indicated that this nsSNP was not associated with RIF 
resistance, but was significantly associated with the Beijing lineage (10). Thus we conclude 
that the 191 A/C nsSNP is a marker identifying isolates from the Beijing evolutionary 
lineage.  Furthermore, this nsSNP can not be used in a genetic test to diagnose RIF 
resistance. Therefore, the rapid diagnosis of RIF resistance is still restricted to analysing 
SNP’s in the RRDR region of the rpoB gene.  
 
Since the early 1990’s, M. tuberculosis isolates from the Beijing evolutionary lineage have 
become the centre of research in many settings. Isolates from this lineage are thought to 
have evolved unique properties, including the ability to evade the protective immunity 
conferred by BCG, as well as the ability to acquire and transmit drug-resistance (11-14). 
However, the functional role of this nsSNP in pathogenesis remains to be determined.  
 
Table1: Characteristics of RIF-susceptible and RIF-resistant M. tuberculosis isolates 
 RIF-resistant (n=90) RIF-susceptible (n=67) 
 WT Rv2629  191A/C Rv2629 WT Rv2629 191A/C Rv2629 
Beijing 0  43 (47.78%) 0 43 (64.18%) 
Non-Beijing 47 (52.2%) 0  24 (35.82%) 0 
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CHAPTER 5 
 
Evidence that the level of Rifampicin resistance in Mycobacterium 
tuberculosis evolves through a multi-step mechanism. 
  
 
 
 
 
 
 
 
 
 
 
 
My contribution: Planning of project 
Literature search 
Culturing of M. tuberculosis clinical isolates  
Rifampicin MIC determination by BACTEC 
Determining the effect of Verapamil/ Reserpine on MIC’s 
Involved in proposing of RIF resistance model 
Writing and editing of manuscript 
 
  
 
65 
 
ABSTRACT 
 
Drug resistance in Mycobacterium tuberculosis has been shown to evolve through 
spontaneous mutation and subsequent antibiotic selection. Resistance to rifampicin (RIF) is 
associated with non-synonymous single nucleotide polymorphisms (nsSNPs) in the rpoB 
gene. Different nsSNPs have been shown to influence the RIF minimum inhibitory 
concentration (MIC) presumably as a result of their varying effects on the structure of the 
β-subunit of RNA polymerase (RpoB). In this study, genetically closely related clinical 
isolates with identical IS6110 and spoligotype genotypes and identical mutations conferring 
resistance to isoniazid, rifampicin, ethambutol and pyrazinamide were selected for RIF 
MIC testing. BACTEC analysis showed that their MICs varied widely despite identical 
nsSNPs conferring resistance. The same phenomenon was observed for genetically 
unrelated RIF resistant clinical isolates. Susceptibility to RIF could be partially restored by 
inhibition of efflux pumps with either Reserpine or Verapamil (p= 0.0000; 95% CI). This 
provides the first evidence that efflux pumps may modulate the level of RIF- resistance in 
clinical isolates of M. tuberculosis over and above the level of resistance conferred by rpoB 
mutations. Accordingly, a model was constructed proposing that the evolution of RIF 
resistance levels is a multi-step process whereby an initial nsSNP confers low level 
resistance, while subsequent mutations and/or gene regulation effects confers varying levels 
of RIF resistance. We conclude that the evolution of strains with varying levels of RIF 
resistance is more complex than the “one mutation – one gene” scenario.  
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INTRODUCTION 
 
Rifampicin (RIF) is one of the most important antibiotics used to treat tuberculosis as it has 
strong sterilizing activity against rapidly growing extra- and intra-cellular Mycobacterium 
tuberculosis bacilli. RIF has been shown to diffuse freely through the cell wall of the 
organism (12) and to inhibit the early steps of gene transcription by binding to the β-subunit 
of RNA polymerase (RpoB) encoded by the rpoB gene (4). Resistance to RIF develops by a 
process of spontaneous mutation and antibiotic selection, particularly during periods of 
poor adherence or monotherapy. Luria-Delbrück fluctuation tests show that mutations 
conferring RIF resistance appears spontaneously at a rate of 10
-9
 to 10
-8
 per cell division 
(5,8). The non-synonymous single nucleotide polymorphisms (nsSNPs) conferring RIF 
resistance occur exclusively in the rpoB gene, with 95% occurring within an 81 bp region 
known as the RIF resistance-determining region (RRDR) (16). Each nsSNP alters the 
structure of RpoB, thereby altering the dissociation constant between the mutated RpoB 
(RpoBmut) and RIF in such a manner that this directly influences the RIF minimum 
inhibitory concentration (MIC) (3,4). Accordingly a direct relationship between specific 
nsSNPs in the rpoB gene and varying MICs could be expected (8). 
 
This study aims to challenge the dogma that a simple relationship exists between nsSNP in 
the rpoB gene and resistance to RIF. We provide evidence to demonstrate that the 
development of RIF resistance is a multi-step process which ultimately defines the level of 
resistance. 
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METHODS 
 
Drug resistant M. tuberculosis bacilli were cultured from sputum samples collected from 
patients attending health-care clinics in the Western Cape, South Africa (15) and 
genotypically characterised by IS6110 DNA fingerprinting (17) and spoligotyping (11) 
using internationally standardised methods. The nsSNPs conferring resistance to isoniazid, 
rifampicin, ethambutol and pyrazinamide were determined by DNA sequencing of the 
katG, inhA promoter, rpoB, embB and pncA genes, respectively. M. tuberculosis isolates 
representing recent MDR-TB outbreaks (defined as having identical IS6110 DNA 
fingerprints, spoligotypes and nsSNP’s conferring resistance to isoniazid, rifampicin, 
ethambutol and pyrazinamide) as well as genetically unrelated drug resistant clinical 
isolates (resistant isolates representative of the same and other evolutionary lineages, 
showing the rpoB Ser531Leu mutation, but different other resistance conferring mutations) 
were selected. In addition, susceptible clinical isolates (RIF susceptible isolates from the 
same evolutionary lineages as the MDR-TB outbreak isolates and showing the same 
IS6110 DNA fingerprints) were selected (9,14,18). 
 
 The MIC for RIF for each of the selected isolates was determined by inoculating a 100 µl 
aliquot of a mid-log phase culture into enriched BACTEC 12B medium (Becton Dickinson, 
USA) containing between 2 to 200µg/ml RIF for the analysis of RIF resistant isolates and 
between 0.0002 to 2µg/ml RIF for the analysis of RIF susceptible isolates in increments of 
10. All cultures were incubated at 37°C and the growth index (GI) for each isolate (at each 
RIF concentration) was measured daily for 9 consecutive days and compared to the GI of 
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the corresponding isolate grown (diluted 1/100) in the absence of RIF. H37Rv (ATCC 
35828) was included as a RIF susceptible control. The MIC for each isolate was defined as 
the lowest concentration of RIF at which there was a complete absence of growth. All 
experiments were done in duplicate in which <5% variation was observed and each 
experiment was repeated on at least two separate occasions.  
 
To determine whether the efflux pump inhibitors reserpine or verapamil had affected M. 
tuberculosis growth in the absence of rifampicin, the selected isolates were cultured in the 
presence of varying concentrations of reserpine (10 to 100 µg/ml) or verapamil (10 to 500 
µg/ml) in enriched BACTEC 12B medium at 37°C (supplementary data). The GI for each 
isolate was measured daily over a period of 9 days and compared to the growth index of the 
corresponding isolate grown in the absence of reserpine or verapamil.  
 
To determine whether reserpine or verapamil could restore RIF susceptibility, the drug 
resistant isolates were cultured at 37°C in enriched BACTEC 12B medium containing 
either reserpine (80 µg/ml) or verapamil (50 µg/ml) together with varying concentrations of 
RIF (2 to 150 µg/ml). These selected isolates represent MDR-TB outbreak strains with 
identical resistance conferring mutations. RIF susceptible isolates were cultured at 37°C in 
enriched BACTEC 12B medium containing either (30 µg/ml) or verapamil (10 µg/ml) 
together with 0.002µg/ml RIF. The GI of both the drug resistant and drug susceptible 
isolates measured daily over a period of 9 days and compared to the growth index of the 
corresponding isolate grown in the absence of reserpine or verapamil but in the presence of 
varying concentrations of RIF.  
  
 
69 
The % susceptibility restored was calculated at day 5 for the isolates by using the following 
formula: 
 
where GIRIF is the growth index of the isolate grown in the presence of only RIF; GIEPI+RIF 
is the growth index of the isolate grown in the presence of both the EPI and RIF; GICONTROL 
is the growth index of the isolate grown without any treatment and GIEPI is the growth 
index of the isolate grown in the presence of only optimal concentrations of EPI.  
 
Statistical analysis to determine the effect of the various treatments over time was done 
using STATISTICA VERSION 7.  
((GIRIF – GIEPI+RIF ) – (GICONTROL – GIEPI)) 
GIRIF 
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RESULTS 
The MICs for RIF were found to be highly variable among isolates representing recent 
MDR-TB outbreaks (clonal expansion) and ranged between 10 and 170 µg/ml RIF in 
BACTEC 12B media (Table 1). This variation was largely independent of the M. 
tuberculosis genotype and the investigated two resistance conferring nsSNP’s (Ser531Leu, 
Asp516Val) in the rpoB gene (Table 1). This variation in the MIC’s for RIF was also 
observed in other drug-resistant isolates (Table 2). Together these results suggest that a 
single rpoB mutation alone cannot explain the variation in the MIC’s for RIF in drug 
resistant clinical isolates. 
 
Table 1: Characteristics of MDR-TB outbreak M. tuberculosis isolates 
  % susceptibility 
restored at 2µg/ml RIF  
 
Isolate 
Evolutionary 
lineage Spoligotype 
IS6110  
cluster 
type 
rpoB 
mutation 
Other 
resistance 
causing genes 
RIF 
MIC  
(ug/ml) 
80µg/ml 
Reserpine 
50µg/ml 
Verapamil  
R279 150 77.29 70.17 
R179 140 69.83 84.63 
R750 90 55.08 76.69 
R405 90 63.13 77.5 
R257 
Beijing 2 220 
TTG 
(Ser531Leu) 
inhA-15prom 
 emb306 GTG 
(Met306Val) 
pncA103 TAG 
(Tyr103Ter) 
30 80.8 84.8 
R451 170 67.58 70.34 
R543 160 67.20 71.03 
R439 
Low Copy Clade 115 DRF150 
TTG 
(Ser531Leu) 
katG315 ACA 
(Ser315Thr)  
emb306 ATA 
(Met306Ile) 
pncA Del58 60 52.67 60.49 
AT970 80 71.56 84.56 
AT720 40 68.25 73.21 
AT787 20 75.10 72.42 
AT881 20 70.18 76.95 
AT802 20 71.23 84.25 
AT776 10 71.46 86.27 
M
D
R
-T
B
 o
u
tb
re
ak
 i
so
la
te
s 
AT695 
Atypical Beijing 2 464 
GTC 
(Asp516Val) 
katG315 ACC 
(Ser315Asn) 
inhA-17prom 
10 62.45 75.12 
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Table 2: Characteristics of genetically unrelated drug resistant M. tuberculosis isolates. 
 
 
Isolate 
Evolutionary 
lineage Spoligotype 
IS6110  
cluster 
type 
rpoB 
mutation 
RIF MIC  
(ug/ml) 
R283 90 
R778 90 
R326 90 
R676 10 
R328 5 
R122 5 
R610 
Beijing 2 220 
TTG 
(Ser531Leu) 
5 
R1040 120 
R1333 120 
R285 100 
R251 
F11 77 1027 
TTG 
(Ser531Leu) 
70 
R74 82 110 
R749 81 110 
R1087 82 80 
R1219 
F28 
81 
11061 
TTG 
(Ser531Leu) 
30 
R58 30 
R212 80 
R223 80 
R432 120 
R440 120 
R779 40 
R1114 70 
R1134 
Low Copy Clade 115 338 
TTG 
(Ser531Leu) 
30 
R32 80 
R160 40 
R607 70 
R733 80 
R794 30 
R1098 80 
D
ru
g
-r
es
is
ta
n
t 
is
o
la
te
s 
R1161 
Low Copy Clade 118 338 
TTG 
(Ser531Leu) 
70 
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In order to determine whether efflux pumps contributed to the regulation of MICs for RIF, 
selected isolates from each of the MDR-TB outbreaks were cultured in the presence of 
varying concentrations of reserpine or verapamil. This study showed that 90% of the 
growth index of each isolate was retained at a concentration of 80 µg/ml reserpine or 50 
µg/ml verapamil (in the absence of RIF), thereby confirming that these compounds at these 
concentrations were not toxic (Figure 1). Susceptibility to RIF was mostly restored when 
the respective MDR-TB isolates were cultured in the presence of 2 µg/ml RIF in 
combination with either 80 µg/ml reserpine or 50 µg/ml verapamil (Figure 1). The 
combined effect of RIF and reserpine and also RIF and verapamil was statistically 
significantly different (p=0.0000; 95% CI) in comparison to the individual drug treatments. 
The percentage susceptibility restored for MDR-TB outbreak isolates varied from 62.45 to 
77.29% for reserpine and 70.17 to 86.25% for verapamil (Table1, Figure 1). This suggests 
that inhibition of mycobacterial efflux pumps by either reserpine or verapamil allowed for 
intracellular accumulation of RIF, thereby promoting the binding of RIF to RpoBmut and the 
subsequent inhibition of transcription. Regulation of susceptibility towards RIF could not 
be demonstrated for drug susceptible isolates (Table 3), thereby suggesting that efflux 
pumps targeted by reserpine or verapamil do not significantly regulate the intracellular 
concentration of RIF in susceptible isolates.  
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Figure 1: The cumulative effect of treatment over time for all the closely related RIF 
resistant isolates.  
Legend to Figure 1: The combined effect of RIF and reserpine and also RIF and verapamil is statistically 
significantly different (p=0.0000; 95% CI) in comparison to the individual drug treatments. The % 
susceptibility restored for genetically closely related strains varied from 62.45 -77.29% for reserpine and 
70.17 to 86.25% for verapamil (Table1). 
 
Table 3: Characteristics of RIF susceptible isolates 
 % susceptibility restored 
at 0.002µg/ml RIF  
 
Isolate Spoligotype 
IS6110  
cluster 
type 
RIF 
MIC  
(ug/ml) 
30µg/ml 
Reserpine 
10µg/ml 
Verapamil  
R284 0.02 4.05 3.97 
R336 0.02 4.88 3.50 
R333 
2 220 
0.02 3.35 3.26 
R166 0.2 2.15 1.96 
R196 0.2 1.78 2.10 
R
IF
 s
u
sc
ep
tb
le
 c
lo
n
es
 
R181 
115 DRF150 
0.--2 3.05 1.73 
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DISCUSSION 
 
In this study we demonstrate that the MIC for RIF varies among drug resistant clinical 
isolates which have different genetic backgrounds and identical nsSNPs in their rpoB 
genes. This was also observed amongst isolates representing different MDR-TB outbreaks 
in different geographical regions in South Africa where both the genetic background and 
rpoB mutation are identical (highly similar) (9,14,18). These findings are consistent with 
the recent report that in vitro selected RIF resistant mutants from two different genetic 
backgrounds, Beijing and non-Beijing, had varying RIF MICs for identical nsSNPs in the 
rpoB gene (8). Thus, in contrast to previous studies which have suggested a direct 
relationship between a specific rpoB mutation and the level of RIF resistance, we conclude 
that the level of resistance to RIF is determined not only by alterations in the structure of 
the β-subunit of RNA polymerase but also by other mechanisms that do not involve rpoB. 
Our results challenge the dogma that nsSNP’s within the rpoB gene are the only 
mechanism conferring RIF resistance and modulating/regulating RIF resistance levels. 
Accordingly, we propose the following multi-step pathway for the evolution of the level of 
RIF resistance. In Figure 2, we define the dissociation constant (Kd
S
) between the “wild 
type” RpoB (RpoBwt) and RIF in a pan-susceptible M. tuberculosis isolates as x nM. 
Following Piddock et al we assume that RIF reaches RpoBwt by passive diffusion and that 
efflux inhibitors do not significantly influence the intracellular RIF concentration, as 
demonstrated in this study. Therefore it is likely that the rate of RIF influx into the M. 
tuberculosis bacillus equals the rate of RIF efflux and thereby the intracellular RIF 
concentration is in equilibrium with the extracellular RIF concentration. 
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Given that the binding affinity of RIF for RpoB is dependent on the structure of the RpoB 
protein (3,4) it can be assumed that spontaneous mutation in the RRDR region will 
influence the dissociation constant (Kd
R
) between the “mutant” RpoBmut and RIF, such that 
Kd
R
 > Kd
S
. The magnitude of Kd
R 
could vary significantly (Figure 2, Step 1). Considering 
the scenario, Kd
R(LOW)
, such isolates would display a MIC of ax nM through passive 
diffusion of a low concentration of RIF, while Kd
R(HIGH) 
isolates would display a MIC of bx 
nM (where b > a) through passive diffusion of a high concentration of RIF. However, 
because isolates with identical nsSNPs demonstrate varying MIC’s we predicted that 
Kd
R(LOW)
 isolates would demonstrate a high MIC for RIF if either secondary mutations 
and/or regulation of gene expression resulted in the active efflux of RIF from the cell 
(Figure 2 Step 2). Thus, a high concentration of RIF would be required to compensate for 
active efflux in order to achieve an intracellular concentration which allowed maximal 
inhibition of RpoB. Conversely, Kd
R(HIGH)
 isolates would display a low MIC for RIF if 
either secondary mutations and/or regulation of gene expression resulted in the active 
accumulation of RIF within the cell (Figure 2 Step 2).  
 
This study supports the above hypothesis by demonstrating that efflux pump inhibitors are 
able to significantly restore RIF susceptibility to the critical concentration of 2 µg/ml. This 
suggests that nsSNPs in the rpoB gene in general confer a low level of RIF resistance. 
When combined with other mutations or expression changes which regulate the 
intracellular RIF concentration, however, the combined changes confer a high level of RIF 
resistance.  
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Our results together with previous results (2,7) suggest that efflux pump inhibitors may 
have an important role in treatment regimens targeted at drug resistant tuberculosis.  This is 
particularly relevant in the context of the limited number of drugs available to treat drug 
resistant tuberculosis and their associated side effects. The restoration of susceptibility to 
perhaps the most important anti-tuberculosis drug (rifampicin) would greatly benefit the 
treatment of MDR-TB and XDR-TB cases. An added benefit would be if efflux pump 
inhibitors could restore susceptibility to more than one drug. This notion is supported by a 
recent study which showed that the level of fluoroquinolone resistance could be 
significantly reduced in M. tuberculosis isolates in the presence of the efflux pump 
inhibitors reserpine or MC207.110 (6).  
 
The introduction to the TB treatment regimen of compounds that restore drug susceptibility 
is an attractive alternative to aid in the control of drug resistance. However, this study was 
done in vitro, and there is a need to assess the efficacy of the potential drugs in vivo 
(although they have been registered for use in humans in treatment of cardiac diseases). It 
has been shown that efflux pump inhibitors such as verapamil and reserpine enhanced the 
killing of intracellular drug-resistant M. tuberculosis bacilli by non-killing macrophages 
(1). Literature suggests that for a drug to be active in patients an antibiotic should have 
Cmax/MIC>10, thus an MIC of 5 ug/ml (Table 2) might not be low enough to reflect 
effective patient treatment from a pharmokinetic point of view (10). A clinical study by 
Prakash et al showed that in patients with TB, pre-treatment with Verapamil, which is also 
a blocker of human P-glycoprotein and cytochrome P450 3A4, increased the serum levels 
of RIF (13).  This suggests that P-glycoprotein and cytochrome P450 play important roles 
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in the absorption of RIF in TB patients. We acknowledge that these efflux pump inhibitors 
have limitations, and encourage the development of novel drugs which modulate the 
intracellular drug concentrations.  
 
We conclude that the evolution of the level of RIF resistance is more complex than the “one 
mutation – one gene – one MIC” scenario. Our study shows that the value of the MIC is 
directly linked to the cumulative effect of different evolutionary events. This implies that 
the bacteriostatic/bacteriocidal efficacy of current drugs may be enhanced by the 
development of compounds which modulate the intracellular drug concentration.  
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Figure 2: Proposed model for the evolution of the level of RIF resistance in M. tuberculosis 
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SUPPLEMENTARY DATA (ADDITIONAL FIGURES) 
 
 
 
Figure 3:  The effect of treatment over time for RIF Resistant isolates to determine the 
optimum concentration of the efflux pump inhibitor; A) RIF resistant isolates without any 
drug exposure serving as control; B) RIF resistant isolate exposed to 50µg/ml Verapamil; 
C) RIF resistant isolate exposed to 80µg/ml Reserpine. 
 
 
 
 
Figure 4: The effect of treatment over time for RIF susceptible isolates to determine the 
optimum concentration of efflux pump inhibitor; A) RIF susceptible isolates without any 
drug exposure serving as control; B) RIF susceptible isolate exposed to 10µg/ml 
Verapamil; C) RIF resistant isolate exposed to 30µg/ml Reserpine. 
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CHAPTER 6 
_________________________________________________________________________ 
 
Rifampicin induces differential expression of putative transporter genes 
in Mycobacterium tuberculosis 
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ABSTRACT 
Central dogma suggests that a single mutation in a specific gene causes a certain level of drug 
resistance and that this resistance cannot be reversed. We have provided evidence in Chapter 5 
that various levels of Rifampicin (RIF) resistance were observed in clinical isolates of 
Mycobacterium tuberculosis with genetically identical backgrounds. In addition, treatment of 
these isolates with efflux pump inhibitors significantly restored RIF susceptibility. This study is 
an expansion of these previous findings. Thirty putative efflux genes were identified by using 
bioinformatics and literature searches for subsequent QRT-PCR assessment. Twenty-eight 
efflux genes were differentially expressed in response to RIF in the LCC cluster DRF150 
strains. Ten genes were up-regulated and 2 genes were down-regulated, irrespective of their 
level of RIF resistance in the LCC DRF150 strains. The remaining 16 genes were uniquely 
differentially expressed in isolates with different levels of RIF resistance. Gene expression in 
Beijing cluster 220 isolates showed differential expression in 21 genes in response to RIF, of 
which 4 genes were up-regulated and 1 gene was down-regulated in both strains. The remaining 
16 genes showed expression levels unique to the isolates with high and low RIF resistance 
levels. The results suggest that a lineage specific global response is firstly launched, followed 
by a subsequent unique response that enables the specific strains to cope with or evade the toxic 
effect of RIF. The results provide the first evidence that putative efflux pumps may contribute 
to variation in the level RIF-resistance in clinical isolates of M. tuberculosis.  
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INTRODUCTION 
Administering of effective drugs is one of the major factors that influence the control of 
infectious diseases. However, due to the emergence of drug resistance in Mycobacterium 
tuberculosis (M. tuberculosis), some anti-tuberculosis (anti-TB) drugs have become 
ineffective. Drug resistance in M. tuberculosis has been primarily associated with mutations 
in defined genes (17). However, in a certain percentage of phenotypically resistant clinical 
isolates of M. tuberculosis, classical mutations known to confer resistance were not 
identified (17). Thus, it was hypothesised that in such cases the M. tuberculosis had adapted 
certain intrinsic mechanisms to evade the toxic and bactericidal effect of the anti-TB drug. 
A number of recent studies have provided experimental evidence to show that efflux pumps 
controlling the intracellular concentration of the anti-TB drug may be candidates 
contributing to drug resistance in mycobacteria (16,27-29). In support of this notion we 
have demonstrated that the addition of efflux pump inhibitors reserpine and verapamil 
largely reversed the rifampicin (RIF) resistance phenotype, despite the presence of a 
mutation in the defined region of the rpoB gene (CHAPTER 5). These efflux pump 
inhibitors generally target ATP Binding Cassette (ABC) transporters.  
 
The completion of the whole genome DNA sequence of several clinical and laboratory 
strains of M. tuberculosis ((http://genolist.pasteur.fr/TubercuList), 
(http://www.broad.mit.edu)) has enabled the identification of various genes which when 
annotated show similarity to transporters in other bacterial species (8,10). Transporters are 
classified based on the direction of drug translocation (i.e. import or export) and their 
energy source (i.e. ATP hydrolysis or proton motive force (pmf)) (5,10). To date, 
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expression studies have investigated the role of transporters in drug resistance. These 
expression studies provide limited understanding of the efflux related drug resistance. An 
example is the increased transcription of the tap-like protein from the Major Facilitator 
Superfamily (MFS) (2), encoded by the Rv1258c gene of M. tuberculosis, upon exposure to 
RIF and INH in a multi-drug resistant isolate (27). The exact role and contribution of these 
transporters to drug resistance remains ill-defined and still needs to be assessed. More 
importantly, the contribution of these putative efflux genes to the level of drug resistance 
has not been investigated yet.  
 
In this study we aim to test the hypothesis that changes in expression of efflux pump 
gene(s) regulate the level of RIF resistance over and above the level of resistance conferred 
by classical rpoB mutations clinical isolates of M. tuberculosis. 
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MATERIALS AND METHODS 
Bioinformatics and literature searches 
The genome sequence of the M. tuberculosis H37Rv reference strain and whole genome 
sequences ((http://genolist.pasteur.fr/TubercuList), (http://www.broad.mit.edu)) of clinical 
strains were searched to identify various types of transporters predicted by bioinformatic 
analysis (Figure 1). In addition, a literature search was done to identify genes which 
showed increased levels of expression in the presence of an anti-TB drug (3,5,10,21,22,25) 
(Table 1).  
 
Selection and growth of M. tuberculosis clinical strains 
Four clinical isolates from 2 genetically distinct evolutionary lineages (Beijing lineage 
cluster 220 and Low Copy Clade (LCC) lineage cluster DRF150), with identical mutations 
in the rpoB gene, lineage specific IS6110 RFLP and spoligotype fingerprint were selected 
based on their levels of RIF resistance (as described in Chapter 5). Resistance levels were 
30 and 140µg/ml RIF for Beijing cluster 220 isolates, and 60, 170µg/ml RIF for the isolates 
in LCC cluster DRF150, respectively (Table 2).  
 
Isolates were grown on Lowenstein-Jensen (LJ) solid medium for 3-4 weeks with 
continuous aeration. Colonies were scraped from the LJ slants and incubated in 5ml 
Middlebrook 7H9 medium (Becton Dickinson, Sparks, MD 21152, USA) supplemented 
with 0.2% (v/v) glycerol, 0.1% Tween 80 and 10% ADC in filtered screw cap tissue culture 
flasks (Greiner Bio-one, Maybachstreet, Germany). After 7-10 days these primary sub-
cultures were inspected for contamination by Ziehl-Neelsen gram staining and culture on 
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blood agar plates. The primary sub-cultures were then sub-cultured in 10ml supplemented 
Middlebrook 7H9 liquid medium and incubated at 37
o
C. After 10-14 days of growth 
(OD600= 0.7-0.8), the secondary sub-cultures were re-inspected for contamination and a 
50% glycerol stock was prepared and stored at -80
o
C.  
 
All subsequent experiments were set up as 2 biological (to assess biological measurements 
for two independent experiments done on different days) and 2 technical replicates 
(repeated measures of one biological sample on the same day) for each isolate. Each 
experimental culture was set up by aliquoting 800µl of the secondary sub-culture in 80ml 
supplemented 7H9 medium (1:100 dilution) and incubated at 37
o
C until mid-log phase 
(OD600= 0.7-0.8). The 80ml culture was then divided into 2 x 40ml cultures. RIF was added 
to one 40ml at a concentration corresponding to ½ the minimum inhibitory concentration 
(MIC) of the respective isolate. No anti-TB drugs were added to the other 40ml culture 
(control). Both cultures were then incubated at 37
o
C for a further 24 hours.   
 
Table 2: Characteristics of the clinical isolates selected 
Isolate Family Spoligotype Cluster IS6110 RFLP 
RIF MIC 
(ug/ml) 
R257
a
 30 
R179
b
 
Beijing 2 220 
 
140 
R439
c
 60 
R451
d
 
LCC 115 DRF150 
 170 
Legend to Table 2: aBeijing RIF-resistant isolate with low RIF resistance levels; bBeijing RIF resistant isolate with high 
RIF resistance levels; cLCC RIF resistant isolate with low RIF resistance levels; dLCC RIF resistant isolate with high RIF 
resistance levels 
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RNA extractions and purification 
After the 24hour incubation, 200 ml of Guanidine-thiocyanate (GITC) (Sigma-Aldrich, St. 
Louis, USA) solution (5M GTC, 0.5% sodium N- lauroyl sarcosine, 0.1M β-
mercaptoethanol, 12.5ml of 1M sodium citrate pH7.0 and 1% Tween 80 made up to 500ml 
with RNase free water)  was added to each 40 ml culture. Cells were harvested by 
centrifugation (3000 x g, 15 min, 20
o
C) and the supernatant was discarded. The pelleted 
cells were then resuspended in 1ml of TRIzol (Life Technologies, Gaithersburg, MD). The 
suspension was transferred to 2ml screw capped tube containing silica beads (IEPSA 
Medical diagnostics, South Africa) and ribolyzed (reciprocal shaker, Hybaid) at 6 W for 20 
seconds. Thereafter the tube was cooled on ice for 1 minute between pulses. The ribolysis 
was repeated 3 times. The samples were centrifuged at 13000rpm for 1min and the 
TRIZOL solution above the beads was transferred to a 2ml phase lock gel tube (Eppendorf, 
Hamburg 22331, Germany) containing 300µl chloroform/isoamyl alcohol (24:1) (Sigma-
Aldrich, St. Louis, Germany). The tube was inverted several times and then centrifuged at 
13000rpm for 10min. The top aqueous layer was transferred to a new 1.5ml tube and the 
crude RNA was precipitated with the addition of an equal volume of isopropanol (Merck, 
Darmstadt, Germany). The samples was then incubated at -20
o
C overnight. The crude RNA 
were collected by centrifugation at 12000 x g, 30 min at 4
o
C and the pellet was washed 
with 70% ethanol (Merck, Darmstadt, Germany). The crude RNA was then collected by 
centrifugation at 12000 x g, for 10 min at 4
o
C, the 70% ethanol was aspirated and the RNA 
pellet was air-dried and dissolved in 70µl RNase-free water.  
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Contaminating chromosomal DNA was digested by typically adding 4µl DNase and 4µl 
DNase buffer (Whitehead Scientific) to 15µl extracted RNA, followed by incubation at 
37
o
C for 30 minutes. The DNase treated RNA was made up to a final volume of 200µl with 
RNase-free water. An equal volume of Phenol:Chloroform (4:1) (Sigma-Aldrich, St. Louis, 
Germany) was added to the diluted RNA, gently mixed and left on ice for 10 min. The tube 
was centrifuged at top speed for 10 min at room temperature. The top aqueous layer was 
transferred to a new tube, 0.1 volumes of RNase-free sodium acetate pH 5.2 and 2.5 
volumes of 100% RNase-free Ethanol (Merck, Darmstadt, Germany) were added. The tube 
was the incubated at -20
o
C overnight. The RNA was collected by centrifugation at 12000 x 
g, 30 min at 4
o
C , washed with RNase-free 70% ethanol (Merck, Darmstadt, Germany), re-
collected by centrifugation at 12000 x g, for 10 min at 4
o
C and the ethanol was aspirated 
off. The purified RNA was air-dried and re-dissolved in 70µl RNase-free water. The 
quantity and quality of the RNA extracted from each culture was determined by measuring 
the A260/A280 ratio spectrometrically, electrophoretic mobility in non-denaturing 1% 
agarose gels stained (Figure 2A) and virtual gel electrophoresis on the Experion Software 
version 2.01 (Bio-rad) (Figure 2B). The RNA preparations were only considered acceptable 
for subsequent analysis if the presence of the dominant 16S and 23S rRNA species 
appeared as fairly sharp bands, the A260/A280 ratio was between 1.8 and 2.1 and no high 
molecular weight DNA was detected. 
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Figure 2 
 
                        
Legend to Figure 2: Visualization of RNA on different systems. A) Assessment of RNA quality by a 
virtual gel (Experion software -BIORAD); B) A typical result obtained on a 1% agarose gel 
 
Primer design for the candidate putative efflux pump genes  
PCR primers (Table 3) for reverse transcription and quantitative amplification of the 
putative efflux pump RNA transcripts were designed using Primer software 3 version 0.2 
(Whitehead Scientific), and the whole genome sequence of the M. tuberculosis H37Rv 
reference strain (http://genolist.pasteur.fr/TubercuList).  
 
Quantitative Real-Time PCR (QRT-PCR) 
cDNA was synthesized from 1 µg of highly purified RNA according to the manufacturer’s 
instructions (QuantiTect Reverse Transcriptase kit (Southern Cross Biotechnologies)). 
Thereafter a 20µl RT-PCR reaction was set up by adding 10µl of 2x Quantitect SYBR 
Green PCR Master Mix (QuantiTect SYBR Green PCR Master Mix (Qiagen)), 1µl forward 
and reverse primer (50µM) of each candidate efflux gene (Table 3), 6µl of RNase-free 
water and 2µl of diluted cDNA (1:10). QRT-PCR was done using a Lightcycler 2.0 system 
(Roche Diagnostics). A four-step PCR parameter protocol was used: (i) Activation program 
A B 
tRNA 
23S rRNA 
16S rRNA 
tRNA 
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(95
o
C for 15 min); (ii) PCR Program repeated for 50 cycles (95
o
C for 3s, 60
o
C for 5s, 72
o
C 
for 20s); (iii) melting curve program (95
o
C for 0s, 60
o
C for 0s, 95
o
C with a heating rate of 
0.2
o
C/s) and a cooling down program of 38
o
C for 10s. Each QRT-PCR experiment was 
done on duplicate biological samples that were each assayed in duplicate. The quantity of a 
specific cDNA in each reaction was determined from the exponential phase of 
amplification from the cycle threshold (Ct). 
 
STATISTICS 
Both 16S rRNA (15) and Rv1437 (27) were included as reference genes, but 16S rRNA  was 
used for normalization of RNA levels, because in the experiments 16S rRNA  expression 
levels were the most stable. The level of gene transcription of each individual gene was 
quantified by the delta-delta Ct calculation in which the relative abundance of the target 
gene was normalized relative to the levels of the reference RNA transcripts (16S rRNA). 
Data analyses were done according to the delta-delta CT equation R=2 
-(LCT sample -LCT control)
 
(20). Only experiments with a standard deviation of <0.5 were included for analysis. 
Significant fold changes were identified based on The Relative Expression Software Tool -
384 (REST-384©) that assigns significance with a significance level of 5%.  
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RESULTS 
Bioinformatic and literature searches identified 30 putative transporter genes in the genome of 
M. tuberculosis which have been suggested to be involved in drug export/import and 
metabolism (Table 1). QRT-PCR was done to determine the expression levels of these genes in 
response to RIF in clinical isolates of M. tuberculosis representative of two different 
evolutionary lineages and different levels of resistance to RIF. Significant differences in the 
level of expression of most of these genes were identified between isolates cultured in the 
absence or presence of RIF (at a concentration equivalent to ½ RIF MIC).  
 
Analysis of the LCC isolates showed that 28 genes were differentially expressed in response to 
RIF (Table 4). No significant gene expression changes were observed for 2 genes (efpA, 
Rv2687c). Ten genes (Rv1463, Rv2994, Rv3806c, mmpL7, drrABC, emrB, iniA, iniC) were up-
regulated (highlighted yellow) and 2 genes (PstB and Rv1002c) were down-regulated 
(highlighted green) in both strains, irrespective of their level of RIF resistance. An additional 
10 genes (highlighted grey) were differentially expressed in the isolate with low level RIF 
resistance (R439), while a further 6 genes (highlighted pink) were up-regulated in the isolate 
with high level RIF resistance (R451). 
 
Similarly, the Beijing strains with different levels of RIF resistance showed differential 
expression of 21 of the selected genes in response to RIF (Table 4). NO significant gene 
expression changes were observed for 9 genes. Four genes (whiB7, Rv1747, Rv3239c, Rv1634) 
were up-regulated (highlighted blue) and one gene (Rv1002c) was down-regulated (highlighted 
red) in both strains. The remaining 16 genes showed different levels of expression between the 
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isolates with high or low RIF resistance levels. The low level RIF resistant isolate (R257) 
showed differential expression of an additional 8 genes (highlighted dark grey), while the high 
level RIF resistant strain (R179) showed differential expression of an additional 10 genes 
(highlighted dark green).  
 
Comparison of gene expression in the isolates from the different lineages showed that only one 
gene (Rv1002c) was down- regulated in both the LCC and Beijing strains. The efpA gene was 
the only gene that was not differential expressed in any of the isolates tested.
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Figure 1: Known transporters associated with drug export in M. tuberculosis 
Legend to Figure 1: ABC– ATP Binding Cassette (21,26); MFS – Major Facilitator Superfamily (19,24); 
SMR- Small Multi drug resistance family (11); RND- Resistance Nodulation Cell Division family (22); INH-
isoniazid, RIF-rifampicin; EMB-ethambutol 
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Table 1: Selection of candidate efflux genes based on bioinformatics and literature searches 
Effux 
Gene 
Possible Drugs 
extruded 
Transporter  Function Protein Product Reference 
PstB INH, RIF, EMB, CIP ABC  
Active import of inorganic 
phosphate and export of drugs 
Phosphate-transport ATP-
binding protein 
(1,4,5,26) 
Rv2686c  CIP ABC Active transport of  drugs 
Integral membrane ABC 
transporter 
(1,5,21) 
Rv2687c CIP  ABC 
Export of highly hydrophobic 
drugs 
Antibiotic transport integral 
protein 
(1,5,21) 
Rv2688c CIP ABC Export of toxic compounds 
Antibiotic-transport ATP-
binding protein 
(1,5,21) 
Rv1747 INH ABC  
Transport of drug across the 
membrane. 
conserved transmembrane 
ATP-binding protein 
(1,5) 
drrA TET, STREP, EMB ABC  
Export of antibiotic in the cell 
wall. 
ATP-binding protein drrA (1,5,6) 
drrB TET, STREP, EMB ABC  
Export of antibiotic in the cell 
wall. 
ATP-binding protein drrB (1,5,6) 
drrC TET, STREP, EMB ABC  
Export of antibiotic in the cell 
wall. 
ATP-binding protein drrC (1,5,6) 
Rv1348 Multiple Drugs ABC 
Active export/translocation of 
drugs across the membrane. 
Probable drugs-transport 
transmembrane ATP-binding 
protein 
(1) 
Rv1456c Undetermined ABC 
Active export of antibiotic 
across the membrane  
Integral membrane protein (1) 
Rv1463 Undetermined ABC 
Active transport and energy 
coupling across the membrane. 
Probable conserved ATP-
binding protein  
(1) 
Rv1258c 
INH, RIF, EMB, 
OFL 
MFS Export of drugs  Conserved membrane protein (1,10,16,27) 
Rv2994 Undetermined MFS Efflux of drugs Conserved membrane protein (10,18) 
Rv1877 
TET, KANA, 
Erythromycin 
MFS Efflux of drugs Conserved  membrane protein (10,18) 
Rv1634 Undetermined MFS Efflux of sugars and drugs 
Drug efflux membrane 
protein 
(9,10,18) 
efpA Possibly INH MFS Export of drugs 
Integral membrane efflux 
protein 
(1,14,18) 
Rv2333c Tetracycline MFS Efflux of drugs 
conserved integral membrane 
transport protein  
(10) 
Rv2459c Drugs MFS Transport of substrates 
conserved integral membrane 
transport protein 
(10) 
Rv3239c Sugar or drugs MFS could be involved in efflux  
conserved transmembrane 
transport protein  
(10) 
Rv3728 Sugar or drugs  MFS Involved in efflux  
conserved two-domain 
membrane protein  
(10) 
emrB Undetermined MFS Export of multiple drugs 
Integral membrane efflux 
protein 
(11) 
mmpL7 INH RND Export of antibiotic 
transmembrane transport 
protein 
(1,13,22,23) 
whiB7 RIF regulatory protein Transcriptional regulation 
transcriptional regulatory 
protein  and effector gene 
(1,27) 
Rv2989 Undetermined 
transcriptional 
regulator 
transcriptional mechanism  
transcriptional regulatory 
protein 
(1) 
iniA INH, EMB Membrane protein Drug transport  INH inductible protein iniA (1,3,7)  
iniB INH Membrane protein Drug transport INH inductible protein iniB .(1,3,7) 
iniC INH Membrane protein  Transcriptional mechanism INH inductible protein iniC (1,3,7) 
Rv1002c Undetermined Membrane protein Unknown function  Integral membrane protein (1) 
Rv3806c Undetermined Membrane protein Unknown Function Integral membrane protein (1) 
Rv3679 Undetermined ATPase Extrusion of  anions Probable anion transporter (1) 
Legend to Table 1: INH- Isoniazid; RIF-Rifampicin; EMB-Ethambutol; CIP-Ciprofloxacin; TET-Tetracycline; STREP-Streptomycin; OFL-
Ofloxacin; KANA-Kanamycin; ABC-ATP-Binding Casssette; MFS-Major Facilitator Superfamily; RND-Resistance Nodulation Cell Division 
Family; SMR-Small Multi-drug resistance Family 
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Table 3: Primers used for QRT-PCR analysis 
Gene Primer sequence Size (bp) Tm (°C) Reference 
Rv1348 
Forward:5`GTT CTT GGG TAC CAC GTT CG 3` 
Reverse:5`GTG GTC GAA CAC CAC AGT TG 3` 
184 60 Current 
Rv1456c 
Forward:5`ATA TGC ATT CGT CGC TGT TG 3` 
Reverse: 5`GGG TAC CCC GGT GAA GTA TT 3` 
170 59 Current 
Rv1463 
Forward:5` AGA ACT GCT CAA GCC CAA GA 3` 
Reverse: 5` ACG TAT TCC GGG TGG ATG TA 3` 
174 60 Current 
Rv1002c 
Forward:5` CAT TTC TGG TGA TGG GCA TT 3` 
Reverse:5` CCA GGT TCC AGG TCT GTT GT 3` 
186 60 Current 
Rv3679 
Forward:5`AAG AAC AAG CTG CCG GTC TA 3` 
Reverse:5` GGC AGC GCT TCT AAC AGA GT 3` 
200 60 Current 
Rv3806c 
Forward:5` GTG TCG TCG GCG TAT TTG AT 3` 
Reverse:5` CGC AGA TAG GTG CTG GTG TA 3` 
200 60 Current 
efpA 
Forward:5` TAG GTT TCA TCC CGT TCG TG 3` 
Reverse:5` TGA CCA GGT TGG GGA AGT AG 3` 
177 60 Current 
Rv1258c 
Forward:5` GGT ATG CCG TGT TGG CTA TC 3` 
Reverse:5` CCG CGT CTG TAT CAC GTA GTT 3` 
188 60 Current 
PstB 
Forward:5’ GTT CCC GAT GTC AAT CAT GG 3’ 
Reverse:5’ ACC ACC AGA GAG TCG AAA CG 3’ 
166 60 Current 
whiB7 
Forward:5’ CAG ACA AAG ATT GCC GGT TT 3’ 
Reverse:5’ TCG AGC CTT GGT CGA ATA TC 3’ 
194 60 Current 
mmpL7 
Forward:5’ TGA AAT ACG GAA GCC TGG TC 3’ 
Reverse:5’ GAG GTA AGA GGC CAG CAC AC 3’ 
197 60 Current 
drrA 
Forward:5’ ACG ACC ATG GTG GAC ATC TT 3’ 
Reverse:5’ AAC ACC AGG TTC TGC TCA CC 3’ 
170 60 Current 
drrB 
Forward:5’ CTG AGC TTG CCC ATT TTG AT 3’ 
Reverse:5’ TCA CCT GTG AGG CTG TCT TG 3’ 
166 60 Current 
drrC 
Forward:5’ AAC CGG TTG CTA ACT CGA TG 3’ 
Reverse:5’ CAG CGG AAC AAT GCT GTA GA 3’ 
153 60 Current 
Rv2686c 
Forward:5’ ACG ACA TTC GAG GAC CCT AC 3’ 
Reverse:5’ ACG ATG ATG CTG GTC AAC AA 3’ 
190 60 Current 
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Table 3: Primers used for QRT-PCR analysis (continued). 
Gene Primer sequence Size (bp) Tm (oC) Reference 
Rv2687c 
Forward:5’ CTA CAG GTG CGG CAG AAG TT 3’ 
Reverse:5’ GAC GAA GAA GAA CCC GAT GA 3’ 
150 60 Current 
Rv2688c 
Forward:5’ ACA GTC CCA CCG AAC TGA AG 3’ 
Reverse:5’ ATG AAT GGT CTC GAC GTG GT 3’ 
164 60 Current 
Rv1747 
Forward:5’ TCT GGA GCT GTT CGT TGA TG 3’ 
Reverse:5’ ACC CAG GAC ATC TGG TCA AG 3’ 
192 60 Current 
iniA 
Foward:5’ AAG ATG ATC CAG CGT CTG CT 3’ 
Reverse:5’TTG ACC TGG CTC AGG ATA CC 3’ 
173 60 Current 
iniB 
Forward:5’ GCT AGC CAG ATC GGT GTC TC 3’ 
Reverse:5’ CGA CAG ATG AGG CAT AGC AG 3’ 
171 60 Current 
iniC 
Forward:5’ CAA CGA CAT TGA ACG ACG AC 3’ 
Reverse:5’ GAA CGG ATC GTT GAG TGG AT 3’ 
179 60 Current 
emrB 
Forward:5’ TTC GAC TAC ATG GGC CTC TT 3’ 
Reverse:5’ TAT GAG CGG ATG TTC TGT GC 3’ 
183 60 Current 
Rv1634 
Forward:5’ CCA CCA ACG AGT TTC TGA CA 3’ 
Reverse:5’ ACC CCA TCA GAT ACG ACG AG 3’ 
174 60 Current 
Rv1877 
Forward:5’ AAT CGC TGT ACC TGG TCG TC 3’ 
Reverse:5’ CGG TCC AGG AAG TTT ACG AA 3’ 
190 60 Current 
Rv2333c 
Forward:5’ TGA TCT TTC TCG ACG CAC TG 3’ 
Reverse:5’ CAG CGT GAA CAA CGA AAC AC 3’ 
200 60 Current 
Rv2459 
Forward:5’TGG ACG TCA ACA TCG TCA AT 3’ 
Reverse:5’GTG ACC CCG AAC ACA AAA CT 3’ 
178 60 Current 
Rv2989 
Forward:5’ GAA AGC GTG CAG GTA TAT CG 3’ 
Reverse:5’ ACA CCG CCT TTG GCA ATA C 3’ 
190 60 Current 
Rv2994 
Forward:5’ CTA TCT CAC GCG GGT CTG TT 3’ 
Reverse:5’ ACA GGA AGA CAC CGA TCC AC 3 
187 60 Current 
Rv3239c 
Forward:5’ CGG ACG CTG ACC CTA TTA GA 3’ 
Reverse:5’ ACA TGC AGT CGA CCG TTG TA 3’ 
200 60 Current 
Rv3728 
Forward:5’ GAT GGC ATC GGA AAA AGT GT 3’ 
Reverse:5’ CAC CAG CTC CAT GAT TTG TG 3’ 
154 60 Current 
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Table 4:  Differential gene expression profile of putative efflux genes  
Fold change after 24hrs exposure to ½ RIF MIC 
LCC cluster  DRF150 Beijing Cluster 220 
Genes 
a
R439 
b
R451 
c
R257 
d
R179 
whiB7 -2.08# 2.89* 5.72* 6.80* 
Rv1456c 1.35 111.43* 1.07 -4.08# 
Rv1463 2.07* 62.90* -1.39 -1.81 
Rv1747 2.34* 1.17 2.16* 7.92* 
Rv2994 2.31* 2.60* 1.90 -2.45# 
Rv1877 -3.28# 2.07* -1.29 -1.36 
Rv2333c -4.79# 1.71 -1.25 -2.22# 
Rv2459c -6.80# 1.41 2.63* -2.92# 
Rv3806c 2.93* 113.77* -1.71 -1.79 
Rv1258c -3.82# -1.42 2.02* 1.10 
efpA -1.61 -1.90 1.34 1.33 
PstB -3.88# -2.64# -2.27# 11.43* 
Rv1002c -2.48# -2.48# -2.76# -8.43# 
Rv1348 -1.21 3.12* -1.38 -1.10 
Rv3679 1.11 152.75* 1.04 3.93* 
mmpL7 3.81* 2.05* 2.93* -1.13 
Rv2686c 2.34* 1.62 -1.40 1.10 
Rv2687c 1.28 -1.93 -2.15# -1.14 
Rv2688c 10.85* -1.49 2.29* 1.32 
drrA 2.45* 2.64* -1.83 -1.64 
drrB 7.16* 4.36* 1.03 3.48* 
drrC 3.52* 2.11* -1.39 1.29 
emrB 4.53* 2.45* 1.85 10.09* 
Rv3728 -8.25# -1.10 1.90 -22.86# 
Rv2989 -6.68# 1.66 1.55 -2.01 
Rv3239c -1.62 2.23 20.32* 4.32* 
iniA 6.32* 2.52* 1.92 -1.55 
iniB 1.28 7.89* 8.93* -10.85# 
iniC 18.06* 3.56* -62.69# 1.21 
Rv1634 7.29* -1.61 89.26* 11.47* 
Legend to Table 4: aLCC cluster DRF150 RIF resistant strain (RIF MIC=60µg/ml); b LCC cluster DRF150 RIF resistant 
strain (RIF MIC=170µg/ml); cResistant strain of Beijing cluster 220 (RIF MIC=30µg/ml); dResistant strain of Beijing 
cluster 220 (RIF MIC=140µg/ml); *significantly upregulated; #significantly down regulated 
                                                                                                                                               
100
DISCUSSION 
 
Efflux pumps are typically membrane proteins that can remove toxic compounds from the 
cell by active transport. Thus such pumps may play an important role in the development of 
resistance to commonly used drugs. This can be affected by either an increase in de novo 
synthesis of the pump itself, the activation of a pre-existing efflux pump through mutation 
or by drug pump interaction. This is supported by the observation that RIF could induce a 
change in expression of the efflux gene (Rv1258c) (27). Our results confirm that most of 
the genes putatively associated with drug resistance through either regulation of influx or 
efflux were differentially expressed in response to RIF. The differential expression of the 
respective efflux genes was largely lineage/isolate specific with the exception of Rv1002c 
which was down regulated in both the isolates from the LCC and Beijing lineages. In this 
study, expression of the efpA gene was not affected by the exposure to RIF. It has been 
shown previously that efpA was up-regulated upon exposure to INH (14). However, this 
efflux gene could not be implicated in conferring drug resistance. 
 
We propose that the extrusion of RIF from the different strains by numerous putative efflux 
pumps may regulate the intracellular concentrations of RIF resulting in different levels of 
RIF resistance. We also suggest that this complex network of differentially expressed genes 
may reflect a response to the toxic nature of RIF at concentrations above the critical 
concentration used in standard drug sensitivity tests. Under these conditions RIF may act as 
an inducer that stimulates expression of the various efflux pumps. Alternatively, the 
hydrophobic nature of the RIF molecule may in itself stimulate the activity of the efflux 
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pumps, as has been shown for aminoglycosides that induce/stimulate specific efflux pumps 
(12). However, the latter effect was not addressed in this study. 
 
Our initial hypothesis suggested that isolates with identical genetic backgrounds would 
respond similarly to the same anti-TB drug pressure. This is in part reflected in our results as a 
number of genes are either up-regulated or down-regulated in a lineage dependent manner. 
We propose that the differential expression of genes seen in isolates from the same lineage 
reflects either differences in the genetic makeup of the closely related strains or that the 
different RIF concentrations used (1/2 MIC) would have had different toxic/killing effects. 
Analysis of the kill curves used to determine the MIC values showed that bacterial growth 
was inhibited by approximately 18-20% at ½ the RIF MIC (sub-inhibitory concentrations) for 
each individual isolate (Chapter 5). Thus we cannot exclude the fact that our observations also 
include a RIF killing effect. This may be reflected by the apparent down regulation of certain 
genes as RIF is a transcription inhibitor. We acknowledge this limitation and suggest that 
exposure to a therapeutic dose may alleviate this confounding factor. 
  
From the results in this study we propose the following: In a rifampicin sensitive strain, the 
addition of RIF will primarily affect the functional activity of rpoB and consequently 
inhibiting transcription. Under such conditions it will be difficult to asses the toxic effect of 
RIF (Figure 5a). With the addition of RIF to a rifampicin resistant strain, the mutation in 
the rpoB gene prevents the binding of RIF to rpoB and thus transcription will proceed. 
Increasing the concentration of RIF will have one of two effects: promote interaction 
between RIF and rpoB leading to inhibition of transcription and cell death or provide a 
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toxic effect to which the cell will react by changing gene expression that will influence 
expression of numerous toxic response genes including efflux pumps (Figure 5b).  It is 
currently unknown whether metabolism of RIF occurs under such conditions to produce 
metabolites which in turn have a toxic effect (Figure 5b). It should be noted that only a 
limited number of efflux pump genes can be stimulated, due to the energy requirements of 
the cell. Depletion of the intracellular ATP pool, would lead to cell death.  
 
From this study we conclude that the level of drug resistance in M. tuberculosis is attributed 
to a combination of mutations in target genes as well as a toxic response which regulates the 
intracellular concentration of the drug.  
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Figure 5: The effect of the addition of rifampicin. A) The effect of the addition of RIF to a RIF 
sensitive strain; B) The effect of the addition of RIF to a RIF resistant strain. 
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CHAPTER 7 
 
CONCLUSION 
 
Drug resistant tuberculosis (TB) has emerged globally despite stringent control strategies. This 
suggests that Mycobacterium tuberculosis has adapted and evolved mechanisms to cope with or 
evade the mode of action of various anti-TB drugs. Rapid diagnosis of patients infected with a 
drug resistant strain is thus of great importance in order to prevent the transmission of these 
difficult to treat strains.  
 
Phenotypic diagnosis of drug resistance remains a lengthy and technically challenging process 
and is not routinely done in many countries with a high burden of drug resistant TB. In South 
Africa, initial drug susceptibility testing (DST) is only done for isoniazid (INH) and 
rifampicin (RIF) on high risk patients. If it is a multi-drug resistant TB (MDR-TB) strain 
(resistant to INH and RIF), then only resistance to ethambutol (EMB) is tested and the patient 
is treated accordingly with second-line anti-TB drugs. No additional DST is done on these 
cultures. Pyrazinamide (PZA) is included in the initial intensive phase treatment regimen for 
TB, together with INH, RIF and EMB. However, due to the technical difficulty in PZA 
phenotypic drug susceptibility testing, PZA resistance testing is not routinely done in South 
Africa. Therefore, the prevalence of PZA resistance in TB patients in South Africa is largely 
unknown. Alarmingly, this study showed that more than 50% of previously treated TB 
patients in the Western Cape of South Africa, are phenotypically and genotypically resistant 
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to PZA. The correlation of phenotypic to genotypic resistance (mutations in the pncA gene) 
was 93%. Although these mutations can be used as a marker to identify PZA resistance, they 
are scattered and highly diverse in the pncA gene (without mutation clustering), thereby 
making it difficult to rapidly identify PZA resistance by genotypic methods other than gene 
sequencing. We also observed that 91% of the PZA resistance was associated with MDR-TB. 
Accurate PZA testing is essential to ensure that patients receive appropriate treatment. The 
failure to detect PZA resistance will result in inappropriate therapy which may lead to 
prolonged treatment. This is a potential crisis, due to the fact that PZA is carried through to 
the next phase when treating patients infected with extreme drug resistant TB (XDR-TB) 
strains. Therefore, this study showed that PZA should not be relied upon in managing patients 
with MDR-and XDR-TB in South Africa.  
 
RIF resistance has been suggested as a marker to identify MDR-TB and a number of 
molecular methods have been employed to rapidly genotype RIF resistance. Recently, an 
additional nucleotide change (Rv2629 191 A/C), other than the known rpoB mutations, was 
identified and shown to be associated with RIF resistance. However, in contrast to what was 
reported, we have shown that this nucleotide change was not associated with resistance to RIF 
but was a polymorphism significantly associated with the Beijing genotype. Therefore, this 
nucleotide change can not be used as a marker for the rapid identification of RIF resistance, 
but it can however be useful in identifying clinical isolates from the Beijing genotype, which 
has a greater propensity to spread and cause disease than other strain families.  
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It is well known that mutations in the rpoB gene confer RIF resistance. It has also been 
accepted that certain mutations confer a certain level of RIF resistance. We have shown by 
using phenotypic methods that the level of RIF resistance varied in closely related clinical 
isolates with identical mutations conferring resistance to RIF, INH, EMB and PZA. This 
observation holds true for different evolutionary lineages, including the Low Copy Clade 
(LCC) and Beijing, which were reported in drug resistant outbreaks in South Africa. We 
therefore conclude that a specific mutation in the resistance conferring rpoB gene alone can 
not explain the variation in the level of RIF resistance in genetically closely related clinical 
isolates. By further investigating this phenomenon, we have shown that the addition of 
compounds that inhibit the activity of efflux pumps (such as verapamil and reserpine), 
together with RIF, significantly reversed the resistance phenotype of the strains to become 
RIF susceptible. For this reason, we proposed a model suggesting that the initial mutation in 
the rpoB gene results in low/moderate resistance and that other unknown mechanisms (eg. 
efflux pumps, regulators or other genes) are responsible for the bacterium becoming hyper-
resistant to RIF. The addition of compounds that inhibit efflux activity has opened a new 
avenue for reviewing existing drugs in combination with anti-TB drugs for the treatment of 
this disease. Apart from normal susceptible TB, this could potentially be promising therapy 
for the treatment of MDR-and XDR-TB. 
 
To further investigate efflux pumps as targets for novel treatment regimens, putative efflux 
genes were identified by bioinformatics and literature searches. Assessment of expression of 
these putative efflux genes by QRT-PCR showed significant differential expression of 
numerous efflux genes in response to RIF for the investigated lineages. In the LCC lineage, a 
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number of the same genes were differentially expressed in both isolates with high and the low 
level of RIF resistance. The same observation was made for the isolates in the Beijing lineage. 
This suggests that a global response is firstly launched to evade the toxic effect of RIF. 
However, isolate specific gene expression changes were also observed in the isolates from the 
different evolutionary lineages, indicating a unique response. This suggests that each isolate 
has adapted to make unique changes in efflux gene expression, in combination with the global 
response, to evade the toxic effect of RIF. Our model suggests that in a RIF resistant strain, 
with an initial defined rpoB gene mutation, RIF has a toxic effect on the cellular functions that 
will result in changes in gene expression. These changes will then stimulate the activity of 
other mechanisms such as the activity of efflux pumps, that will ultimately regulate the 
intracellular drug accumulation and subsequent level of RIF resistance. 
 
Initial whole genome sequence of the same low and high level rifampicin resistant clinical 
isolates that were used in this study indicate that only a few SNP’s and indels are different 
between these two sets of strains. Since there are only a few differences it will not be difficult 
to assess functionality of potential candidates by point mutagenesis and knock in/out of genes.  
This will lead to the unravelling of the mechanisms leading to the development of RIF hyper-
resistance in well characterized clinical isolates. However, comparative sequence analysis of 
more isolates is essential to get a full picture of the evolution of drug resistance. New targets 
identified from comparative sequence data will be useful for future drug design.  
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Future studies will include the assessment of the effect on efflux pump inhibitors on in vitro 
laboratory-generated mutants, as it has been reported that the level of RIF resistance also 
differs in these isolates with identical mutations.  
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